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Amyotrophic Lateral Sclerosis is a neurodegenerative disorder characterized by 
progressive muscle denervation, motor axon degeneration and the death of 
motor neurons. The molecular mechanisms that mediate axon degeneration in 
ALS remain unknown, but motor neuron cell body death occurs through 
apoptosis. Genetic deletion of the pro-apoptotic gene Bax delays muscle 
denervation, prolongs disease onset, prevents motor neuron cell death and 
improves survival in an ALS mouse model. However, the timing and extent of 
axon degeneration in these mice is unaffected. Here, we examine the role of 
Sarm1, a component of the Wallerian degeneration pathway, and its interaction 
with the classical apoptotic cascade in ALS. Consistent with previous work, we 
find that genetic deletion of Bax delays symptom onset and extends lifespan of 
SOD-1G93A transgenic mice.  In contrast, elimination of Sarm1 modestly delays 
axon degeneration at later stages of the disease without affecting lifespan. 
Genetic block of both pathways delays symptom onset, prolongs survival, and 
decreases disease burden by significantly reducing, by half, the number of days 
that mice exhibit disease-related symptoms. Our results demonstrate divergent 
and mutually reinforcing roles for the apoptotic and Wallerian degeneration 
pathways in ALS and suggest the presence of a molecularly distinct pathway that 
mediates disease progression. 
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Chapter 1: Introduction and Overview of the Field 
Rationale 
Neurodegenerative disorders are characterized by the disruption and 
death of neuronal cells. Different neurodegenerative diseases result in a loss of 
distinct neuronal cell types, particularly in their early stage. For example, 
Alzheimer’s disease is mainly characterized by the loss of cortical neurons, 
Parkinson’s affects dopaminergic neurons in the substantia nigra, Huntington’s 
causes death of striatal neurons in the basal ganglia, and amyotrophic lateral 
sclerosis (ALS) is specific to motor neurons and corticospinal neurons. While 
different neuronal cell types are affected, there is evidence that similar cell death 
pathways are active during degeneration in these unique diseases. In this study, 
we will focus on neuronal cell death of motor neurons in ALS, but hope that 
elucidation of these cell death mechanisms may be applied more broadly to 
neuron degeneration in neurodegenerative diseases, in general. 
Amyotrophic Lateral Sclerosis (ALS) is a fatal disorder that results in 
degeneration of motor neurons located in the brain and spinal cord, which leads 
to paralysis and eventual death. Studies have described ALS as a “dying back” 
disorder, which begins with disruption in synaptic connections at the 
neuromuscular junction, followed by axon degeneration resulting in motor neuron 
cell death (Fischer et al, 2004). While the anatomical features of the disease 
2 
have been well documented, the underlying molecular mechanisms remain 
unknown. 
Since axon degeneration precedes motor neuron loss, we thought by 
targeting mechanisms of axon degeneration we might be able to delay onset or 
prevent disease progression in an ALS mouse model. The work in this thesis 
examines an approach to target an axon degeneration mechanism known to be 
involved in other motor neuronopathies that is distinct from other cell death 
pathways. Since it is already known that the apoptotic pathway is involved in 
ALS, we further attempt to elucidate the interaction of these two pathways in a 
murine model of ALS. 
Amyotropic Lateral Sclerosis Prevalence and Types 
Amyotrophic Lateral Sclerosis (ALS), sometimes referred to as Charcot’s 
sclerosis (named after Jean-Martin Charcot who discovered the disease) or Lou 
Gehrig’s disease, is a rapidly-progressing adult-onset neurodegenerative 
disorder characterized by degeneration of upper and lower motor neurons, which 
leads to paralysis and eventual death (Cleveland and Rothstein, 2001) (Figure 
1.1). ALS has a prevalence of about 2 per 100,000 total cases each year 
(O’Toole et al, 2004), with multiple studies showing an increased risk in males 
(Vazquez et al, 2008). The average age of onset for a typical ALS patient is 
between 50-65 (Logroscino et al, 2008; O’Toole et al, 2008) and progression of 
the disease is typically very rapid with the time from disease onset until death 
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ranging from three to five years. While most cases of ALS have a late onset and 
fast progression, 5% of cases are juvenile forms where onset occurs much earlier 
between the ages of 20-40 (Andersen et al, 2011). These juvenile cases usually 
progress more slowly from onset until death and predominantly affect so called 
upper motor neurons (i.e., corticospinal tract neurons, with cell bodies in layer V 
of the cortex) (Pupillo, et al, 2014; Zoccolella et al, 2008; Sabatelli et al, 2008). 
About 10% of ALS cases are inherited as an autosomal dominant trait 
(Leblond et al, 2014; Sreedharan et al, 2013) with the remaining 90% caused by 
sporadic mutations. Familial ALS (fALS) and sporadic ALS (sALS) both have 
similar pathological hallmarks (Boillée et al, 2006; Ferraiuolo et al, 2011) 
including progressive muscle weakness, atrophy, and spasticity (Amato et al, 
2008) with denervation of the respiratory muscles as the fatal event for most 
patients. The type of mutation does seem to affect the site of onset of the disease 
with some sites resulting in a more aggressive form of ALS. For example, ALS 
patients with onset in the bulbar muscles have a mean survival of 2 years (Chiò 
et al, 2011). This shows that some patients do have a genetic component, 
however pathology at autopsy is very similar in ALS patients with different 
mutations (Iwanaga et al, 1997). 
Patients with either fALS or sALS can develop frontotemporal lobar 
dementia (FTLD) as well. FTLD is characterized by degeneration of layer V 
neurons located in the frontotemporal lobe of the cortex, which results in 
behavioral changes (Figure 1.1). 25% of patients with ALS display clinical FTD 
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(Swinnen, et al 2014) through language abnormalities, disinhibition, delusions 
(Strong et al, 2011; Mioshi et al, 2014), and depression (although whether 
depression is caused by cognitive changes or reactive depression is difficult to 
tell) (Ferrari et al, 2011). 
Figure 1.1 Illustration of areas affected in ALS. Upper motor neurons (UMN) 
(in blue) and lower motor neurons (in red) are the areas affected in both familial 
and sporadic ALS. 25% of these cases are associated with degeneration in layer 
V of the frontotemporal lobe (in orange). Degeneration of each of these 
components causes different phenotypes listed in the blue box for UMN 
degeneration and the orange box for LMN degeneration (Swinnen, et al 2014). 
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Genetic and molecular underpinnings of ALS 
Over the past few years, great progress has been made in determining the 
genetic etiology of ALS, which has in turn led to insights into molecular 
mechanisms of neurodegeneration. ALS was thought initially to be a non-
hereditary disease. It wasn’t until 1955 that a hereditary form was identified 
(Kurland and Mulder 1955). As mentioned above, 10% of ALS cases have been 
identified as familial with the rest labeled as sporadic, but in part caused by 
identifiable mutations. Currently, the genetic etiology of two-thirds of fALS and 
11% of sALS are known to be caused by genetic mutations (Figure 1.2). 
Fig 1.2 Mutations that cause familial and sporadic forms of ALS. Genes with 
mutations found to cause familial (top circle) or sporadic (bottom circle) forms of 
ALS. Each color identifies one gene including C9ORG72 (green), FUS (light 
blue), TARDBP (dark blue), SOD-1 (purple), other genes that contribute including 
OPTN, VCP, SQSTM1, PFN1, UBQLN2 (yellow) and unknown (red). The number 
in the middle of the circle represents the total fraction of either fALS or sALS 
cases (Renton et al, 2014).  
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The first gene mutation identified in an ALS patient was in the superoxide 
dismutase-1 (SOD-1) gene (Rosen et al, 1993). The next gene, TARDBP, was 
not identified until fifteen years later (Sreedharan et al, 2008). Advances in 
technology and computation, such as GWAS studies, have led to the discovery of 
many more contributing genes in recent years, including fused in sarcoma (FUS), 
valosin-containing protein (VCP), optineurin (OPTN), ubiquilin 2 (UBQLN2), 
sequestosome 1 (SQSTM1) and a hexanucleotide repeat expansion in C9ORF72 
(Kwiatkowski et al, 2009; Vance et al, 2009; Johnson et al 2010; Renton et al 
2011; DeJesus-Hernandez et al, 2011; Maruyama et al, 2010) (Figure 1.2 and 
Table 1.1). 
Table 1.1 Genes known to carry ALS-causing mutations. Genes identified to 
be mutated in ALS (first column), location of gene on the chromosome (second 
column), how the gene is inherited as autosomal dominant (AD), autosomal 
recessive (AR) or X-linked dominant (XD) (third column), percentage of cases in 
which this gene has been shown to cause either fALS or sALS (fourth and firth 
column, respectively), and putative protein function (sixth column) (Renton et al, 
2014). 
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Other genes have also been identified in rare cases to cause ALS or ALS-like 
pathology (Hadano et al, 2001; Eymard-Pierre et al 2002; Chen et al, 2004; 
Duqette et al, 2005) (Table 1.2). 
Table 1.2 Other genes implicated in the pathogenesis of ALS. Multiple 
additional genes have been reported with rare mutations that can cause ALS. 
Most of these mutations cause a juvenile onset, slower progressing version of the 
disease. Column labels are similar to Table 1.1 and listed in above legend. 
8	  
Some commonalities between protein function of mutated genes in ALS 
have been found, such as RNA metabolism dysfunctions in the TARDBP and 
FUS genes, proteasome and vesicle transport defects in VCP, OPTN and 
UBQLN2, and axonal transport and vesicle trafficking defects in various slow 
progressing and juvenile onset forms, but there does not seem to be one 
overarching theme of protein function that is deregulated in motor neuron 
degeneration in ALS, since many different types of dysfunctions can cause ALS 
symptoms. 
SOD-1 function and mutations 
As mentioned above, the first gene mutation identified to cause familial 
ALS was in the gene encoding superoxide dismutase 1 (SOD-1) (Rosen et al, 
1993). 20% of the 10% of fALS cases have been attributed to SOD-1, making up 
2-5% of all ALS cases. SOD-1 encodes a cytosolic, Cu/Zn-binding protein that 
catalyzes the conversion of toxic superoxide O2- to O2 and H2O2 (Fridovich, 
1976). SOD-1 is located in the cytosol, nucleus, peroxisomes, and mitochondrial 
intermembrane space (Fridovich I, 1997; Okado-Matsumoto et al, 2001; Sturtz 
LA et al, 2001). 
Although the function of SOD-1 is known, it has been very difficult to 
determine the nature of its dysfunction in ALS. This is because over 100 different 
mutations have been identified in the SOD-1 gene to cause ALS (Valentine et al, 
2004), but these mutations vary in biochemical properties, stability, and protein 
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function (Hayward et al, 2002; Rodriguez et al, 2002; Tiwari et al, 2003). Mutated 
sites include positions in the metal-binding ligand or electrostatic loop that might 
perturb metal binding affinity, positions at the disulfide bond where protein 
stability might be affected, and truncations that would not allow dimerization to 
occur. On the other side of the spectrum, many SOD1 mutations occur in 
locations far away from critical areas of protein function. Some of the mutant 
forms of SOD-1 retain nearly normal SOD1 activity. It is therefore thought that 
mutant SOD-1 exerts its effect through a gain of function mutation. This 
conclusion is further supported by a lack of an ALS phenotype in SOD-1 deficient 
mice (Reaume et al, 1996) or mice overexpressing human wild-type SOD-1 
(Gurney et al, 1994). 
Mutations that affect different SOD1 functions also do not correlate with 
survival times. Mutations in human SOD1 that result in an activity similar to WT 
SOD1 show a greater than seventeen-year survival for G37R, G41D, and E100K, 
about ten year survival for G93C, about five years for E100G, one to three years 
for L38V, H43R, and G93A, and one year for A4V (Orrell et al, 1999; Parton et al 
2002). Mutations in SOD1 found in the metal binding region have similar 
variability with a greater than seventeen-year survival for H46R (Abe et al, 1996), 
six years for G85R (Juneja et al, 1997), and very short survival times for H48Q 
and S134N. 
Information on how mutations in SOD1 affected its activity levels came 
from studies in yeast. Human WT SOD1 and multiple SOD1 mutant proteins, 
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including A4V, G37R, L38V, G41D, G85R, G93A, G93C, and I113T, rescued the 
O2- negative phenotype of the sod1Δ yeast strain (Rabizadeh et al, 1995; Corson 
et al, 1998). H46R and H48Q mutant SOD1 did not rescue this phenotype 
(Ratovitski et al, 1999), indicating that SOD-1 activity is not the cause of the ALS 
phenotype. 
There is some evidence that mutated SOD-1 protein aggregates in ALS, 
which is similar to what is seen in other neurodegenerative disorders, such as aβ 
plaques in Alzheimer’s disease and Lewy bodies in Parkinson’s disease (Soto et 
al, 2003; Valentine et al, 2003). Mutated SOD-1 human patient samples have 
been found to have inclusions containing neurofilament, ubiquitin, and SOD1 
protein aggregates. These protein aggregates are not thought to be toxic since 
accumulation occurs during late stages of the disease (Morrison et al, 1998). 
However, high molecular weight oligomers of SOD1 are found well before 
disease onset in mice expressing mutant SOD1 so this evidence does indicate 
that mutant SOD1 does differ in some feature from its wild type form to allow for 
oligomerization (Wang et al, 2002; Johnston et al, 2000). 
SOD-1 transgenic mouse models to study ALS 
Multiple mutant SOD-1 transgenic mouse models have been created that 
reproduce the human disease phenotype (Wong et al, 1995; Bruijn et al, 1997; 
Ripps et al, 1995; Brännstöm et al, 2000). Transgene copy number of mutated 
SOD-1 has been found to be important in determining disease phenotype. High 
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transgene copy number causes early onset and a rapidly progressive disease, 
whereas low transgene number causes a late onset and a slower progressing 
form (Dal Canto et al, 1995; Dal Canto et al, 1997). Three well-characterized 
transgenic SOD1 mutant lines are the G93A (Nagai et al, 2001), G37R (Wong et 
al, 1995) and the G85R (Bruijn et al, 1997) mutation, each expressing a high 
transgene copy number. 
Although disease onset and survival vary among transgenic mouse 
strains, many pathological features remain constant and comparable to ALS 
patients. Hind limb weakness and tremors usually occur at symptom onset, 
followed by progressive motor paralysis and eventually death. The early onset, 
fast progressing transgenic mouse model, SOD1G93A, dies around four to five 
months. The gray matter of the motor neuron system is most dramatically 
affected in mutant SOD1 trangenic mice, specifically the ventral horn and 
brainstem motor nuclei, which are not affected in non-transgenic or WT SOD-1 
overexpressing mice (Wong et al, 1995; Brujin et al; 1997; Ripps et al 1995; 
Gurney et al 1994; Friedlander et al 1997). In transgenic mice with high SOD-1 
copy number, lesions have also been seen to extend into other areas such as the 
dorsal horn of the spinal cord, vagal nerve dorsal nuclei, brainstem reticular 
formation, substantia nigra, cerebellum, and thalamus. 
Numerous malfunctions of various biological processes have been 
identified in ALS mouse models including protein aggregations, mitochondrial 
abnormalities, axonal transport dysfunction, dysregulation of calcium metabolism, 
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high glutamate levels, and oxidative damage (Brujin et al, 2004, Ilieva et al, 2007, 
Lev et al, 2009). Interestingly, the morphological changes in lower motor neurons 
seem to occur in a “dying back” fashion in mice (Frey et al, 2000). This 
phenotype is manifested through weakening at the synapse, followed by axon 
degeneration, which precedes motor neuron cell body loss. This phenomenon is 
not unique to ALS, since this type of disease progression is also seen in 
progressive motor neuropathy mouse models (Schmalbruch et al, 1991). Studies 
have elucidated similar spatiotemporal progression of the disease in an 
SOD1G93A transgenic ALS mouse model (Fischer et al, 2003). 
It has been well reported that a pathological phenotype precedes disease 
onset. Fischer et al. (2003) discovered that neuromuscular junction (NMJ) 
denervation begins at day 47, while clinical stages of the disease do not occur 
until day 80. This study also pointed out that ventral root motor axons were 
affected between these two timepoints and a loss of alpha motor neurons (the 
vulnerable subtype of motor neurons in ALS) did not occur until day 100 (Figure 
1.3). This same study also analyzed a 58-year-old ALS patient who died 
unexpectedly before undergoing full progression of the disease. Samples from 
this patient showed atrophy in leg muscles, but very little axon degeneration. 
Also, motor neuron number in the spinal cord was normal. This case is anecdotal 
and therefore cannot be used to generalize a common pathology in mice and 
humans, but is an indication that something similar might be occurring. 
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Fig 1.3 Histological analysis of SOD-1G93A Tg mouse model throughout 
disease progression. A) Percentage of neuromuscular junction innervation 
(white), partially innervated (gray), and denervated (black) at various timepoints 
throughout disease. B) Percentage of axon degeneration at various timepoints. 
C) Number of neuron cell bodies in the ventral horn at various timeopints. Red
boxes indicate the timepoint where significant loss is seen of each parameter 
(Fischer et al, 2003).   
Other groups went on to characterize the loss of neuromuscular junction 
innervation in more detail. The hindlimb muscles are dramatically affected at 
early stages and throughout the disease and are therefore the major site 
analyzed in many studies. The mouse hindlimb contains three major muscles that 
have been analyzed extensively. These include the gastrocnemius, the tibialis 
anterior, and the soleus muscles. Each of these muscles contains a different 
composition of fast and slow twitch fibers. The gastrocnemius and tibialis anterior 
muscles are composed mostly of fast twitch fibers, referred to as Type IIB fibers. 
The soleus muscle is made up mostly of slow fibers, or Type IIA fibers. 
Neuromuscular denervation            Axon degeneration    Cell body loss 
Time (days) 
A B C 
Time (days) Time (days) 
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Identification of a third category of muscle, the Type IID fibers, is intermediate 
between the fast and slow fibers. Fast fibers rely on more glycolytic mechanisms 
for metabolism, while slow fibers use oxidative mechanisms. Type IID fibers use 
a combination of both of these mechanisms, but are still categorized as fast 
fibers. 
EMG recordings of whole muscle and motor unit contractile forces were 
taken from both fast and slow muscle fibers at different timepoints in a 
SOD1G93A transgenic mouse model (Hegedus et al, 2007).  They found that 
there was an initial loss of fast motor unit function, but not slow motor units. Slow 
motor unit loss occurred later and the loss of overall motor units in the hind limb 
plateaued during symptomatic stages of the disease. These results are 
consistent with immunohistochemical evidence showing that denervation occurs 
in a muscle specific manner. This makes sense since fast motor units innervate 
fast muscle fibers and slow motor units innervate slow muscle fibers. 
It is thought that clinical symptoms occur after denervation due to the 
ability of the remaining axons that innervate slow fibers to reinnervate muscle 
fibers through collateral sprouting. Motor axons that innervate fast fibers, the 
most vulnerable type, are not able to sprout and reinnervate target muscles, 
while the axons that innervate slow fibers retain this ability (Frey et al, 2000). 
Compensatory sprouting occurs until a critical point is reached where 
reinnervation is unable to substitute for the increased denervation, which is when 
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muscle weakness or symptomatic stages of the disease occur (Felice et al, 1997; 
Hayworth et al, 2009). 
It has been shown that large caliber axons are the most susceptible in an 
SOD1G93A mouse model (Feinberg et al, 1999, Bendotti et al, 2001, Fischer et 
al, 2003). Others have provided further insight into the mechanisms underlying 
this vulnerability (Pun et al 2006). The large size of the axons might indicate a 
greater dependency on axonal transport. This is consistent with studies that 
show perturbations in various axonal transport proteins can cause symptoms of 
ALS in motor neuron diseases and have also been identified in the SOD1G93A 
mouse, specifically neurofilament aggregates. Other studies have shown 
enlarged mitochondria in the distal part of large axons in the sciatic nerve of the 
SOD1G93A mouse at presymptomatic stages of the disease and in sporadic ALS 
patients (Siklos et al, 1996, Dadon-Nachum et al, 2011). 
Multiple studies identify synapses at the NMJ as a vulnerable location for 
motor neuron axons. A few hypotheses currently exist, but no one abnormal 
function has been attributed to synaptic dysfunction leading to axon 
degeneration. Some information is known about the mechanisms of cell body 
loss following axon degeneration, which will be discussed in later sections. 
Cell autonomous mechanisms in ALS 
Descriptive studies examining the anatomical features of motor neuron cell 
death in the mutant SOD-1 disease mouse model led many to believe that the 
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disruption was occurring in neuronal cells. The first evidence that mutant SOD-1-
mediated cell death was not solely neuronal came from evidence where human 
mutant SOD-1 was expressed exclusively in motor neurons, but did not cause 
ALS symptoms (Pramatarova et al, 2001). The SOD-1G37R high transgene copy 
number was driven under the neurofilament promoter and although mutant SOD-
1 expression was high in motor neurons in the spinal cord, no cell body loss in 
the spinal cord or axon degeneration in the ventral root was observed. In 
addition, there was no effect on motor performance when testing motor function 
using the limb grip strength test. 
Other work pointing to a non-cell autonomous component driving ALS was 
work from Clement et al, who showed that the ALS phenotype observed in the 
SOD-1 mutant mouse was driven by a combination of cell autonomous and non-
cell-autonomous processes. In this study, researchers created mutant SOD-1 
chimeric mouse lines that express both mutant SOD-1 and WT cells and showed 
that non-mutant SOD-1 motor neurons develop an ALS pathology, specifically 
SOD-1 aggregate and ubiquitin accumulation, which causes these WT cells to 
atrophy. This group also went on to show that nonneuronal non-mutant SOD-1 
cells can delay or prevent degeneration of ventral root axons and motor neuron 
loss in the spinal cord and ultimately result in an extended lifespan in these 
chimeric lines compared to SOD-1 mutant lines (Figure 1.4) (Clement et al, 
2003). 
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Fig 1.4 ALS includes cell autonomous and non-cell autonomous 
mechanisms. A) Chimeric SOD1G85R and SOD1G37R mutants were created by 
injecting WT YFP expressing ES cells into SOD1G85R and SOD1G37R mutant 
animals at the blastocyst stage. B) Survival curve showing extended survival in 
chimeras vs. mutant SOD-1 lines. C) Number of neurons in ventral spinal cord 
per field quantified for WT, SOD-1G37R, and two chimeric lines (#646 and #213) 
where the left side contained WT expressing YFP cells and the right side did not. 





showing degeneration in right side without WT expressing-YFP cells and E) 
motor neurons in spinal cord degenerated without WT non-neuronal cells 
present. (Clement et al, 2003) 
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Since this finding, other groups have tried to identify the source of the non-
cell autonomous toxic effect. There are conflicting results in the field as to what is 
the driving factor that causes SOD-1 mediated toxic cell death. Nagai et al 
isolated conditioned medium from mutant SOD-1 astrocytes and found it to cause 
primary motor neuron cell death (Nagai et al, 2007). Other labs have identified 
microglia as the major contributor to motor neuron cell death in vitro (Fig 1.5) (de 




Figure 1.5 The role of non-cell autonomous mutant SOD-1 on motor 
neurons in vitro. A) Isolation and identification of motor neurons through Hb-9-
GFP and ChAT staining. B) Conditioned medium from mutant SOD-1 astrocytes, 
but not any other cell type shows motor neuron cell death. C) Another study 
shows motor neurons cultured with mutant SOD-1 microglia (bottom panel) have 
an even greater cell death effect than when cultured with mutant SOD-1 
astrocytes (top panel). Red bar = SOD-1G93A treated, White bar = Non-transgenic 
treated (Nagai et al, 2007 A, B; de Boer et al 2014 C). PMN = primary motor 
neuron 
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Mechanisms of Apoptosis 
The apoptotic pathway involves a complex series of steps that can be 
activated through multiple avenues. Apoptosis can proceed through the death 
receptor (extrinsic) or the mitochondrial (intrinsic) pathway (Figure 1.6). The 
death receptor mediated pathway can be initiated through ligand binding to 
receptors such as Fas/CD95 and tumor necrosis factor receptor 1 (TNFR1). This 
binding allows these receptors to aggregate “death domains” intracellularly that 
can then aggregate adaptor proteins, Fas associates with FADD and TNFR1 
associates with FADD and TRADD. FADD and TRADD contain death domains, 
which are then able to recruit and activate pro-caspase 8 (Vila and Pzedborski 
2003). 
The mitochondrial or intrinsic pathway can be activated through a death 
receptor-independent mechanism. Various stimuli trigger translocation of pro-
apoptotic effectors including Bax and its relative Bak, to the mitochondria. Bax 
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and Bak localize to the mitochondrial outer membrane to allow for 
permeabilization and subsequent release of cytochrome c into the cytosol. 
Cytochrome c is then able to interact with other proteins, specifically procaspase 
9 and Apaf1 (Li et al, 1997) leading to the cleavage and activation of the initiator 
caspase, Caspase-9 (Hengartner et al, 2000). Catalytically active caspase-9 can 
then further activate downstream effector caspases, such as caspase-3 and -7 
(Liu et al, 1997; Sakahira et al, 1998). Caspase-3 is the first step in the pathway 
that can both be activated by the intrinsic and extrinsic pathways. 
In addition to activators of apoptosis, there are also known inhibitors and 
modulators of the apoptotic pathway. A well-known family of proteins that can 
inhibit apoptosis are the pro-survival Bcl-2 family members. This group consists 
of Bcl-2, Bcl-xL, Bcl-w, Mcl1, Bcl-B, and A1. There are also a group of pro-
apoptotic family members including Bad, Bim, Bid, Hrk, Noxa, Puma, and BMF 
(Figure 1.6) (Adams and Cory, 1998; Youle and Strasser, 2008). The pro-survival 
family members, such as Bcl-2 and Bcl-xL have been shown to inhibit Bax and 
Bak by direct binding (Willis et al, 2007). 
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Figure 1.6 Apoptotic Pathway Schematic. The apoptotic pathway can either be 
initiated through the death receptor-mediated (extrinsic) or the mitochondrial 
(intrinsic) pathway. Both lead to downstream activation of effector caspases. The 
intrinsic pathway can be initiated through a number of different stress signals, 
which lead to colocalization of Bax and Bak to the mitochondria. This results in 
outer membrane permeabilization and release of cytochrome c into the cytosol. 
Pro-caspase-9 is then cleaved to its active initiator caspase-9 form which can 
then cleave downstream effector caspases such as Caspase-3 and -7 (Illustrated 
by David Simon). 
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The role of the apoptotic pathway in ALS 
There is increasing evidence to suggest that motor neuron degeneration in 
ALS occurs at least partly by a programmed cell-death mechanism (PCD). The 
initial evidence that led investigators to believe that apoptosis plays a role in ALS 
came from observations in vitro of transfected neuronal cells expressing mutant 
SOD1 (Rabizadeh et al, 1995) and primary neurons grown from mutant SOD1 
transgenic mice (Ghadge et al, 1997) dying by apoptosis. Cells undergoing 
apoptosis have unique changes that occur including plasma membrane blebbing, 
contraction of cytoplasmic organelles and chromatin condensation and 
fragmentation. Interestingly, dying neurons in mutant SOD1 transgenic lines 
exhibit some of the attributes of apoptosis such as the condensed chromatin, but 
overall the morphology is indicative of a nonapoptotic mechanism that closer 
resembles autophagy or necrosis (Clarke, 1999). 
There are conflicting results regarding another key feature of apoptosis, 
that is, fragmentation of DNA. One study observed differences in DNA 
fragmentation in ALS patients vs. controls, but these studies were unable to be 
replicated in either ALS patients or animal models (Yoshiyama et al, 1994, Martin 
et al 1999, Migheli et al, 1999, Migheli et al, 1994, He et al, 2000). In determining 
the PCD mechanism, it is common that the morphology of cells lie on a spectrum, 
therefore a possibility is that multiple PCD pathways may be involved in ALS 
since the morphology of dying motor neurons does not exactly replicate 
traditional apoptotic morphology. 
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While the morphological data of whether apoptosis is involved in ALS is a 
little ambiguous, there are other more solid approaches that have been explored 
in determining the apoptotic pathway’s role in ALS. One such approach is looking 
at expression or through genetic manipulation of apoptotic factors in mutant 
SOD1 mouse models. 
Vukosavic et al showed that Bcl-2 and Bcl-xL (two anti-apoptotic family 
members) had decreased expression levels at endstage of the disease 
compared to earlier asymptomatic stages and non-transgenic animals (Fig 1.7) 
(Vukosavic et al, 2000). Further evidence supporting the role of Bcl-2 in ALS is 
seen by delayed symptom onset and extended survival in a mutant SOD-1 
transgenic animal overexpressing bcl-2 (triangles in Figure 1.7) (Kostic et al, 
1997). 
Initiators of apoptosis were also found to play a role in ALS mouse 
models. Bax, a component of the apoptotic pathway that can be triggered by 
stress signals, has also been shown to be upregulated in an ALS mouse model 
at endstages of the disease compared to asymptomatic stages or in non-
transgenic animals (Fig 1.8A) (Vukosavic et al, 1999). Another group examined 
further the localization of Bax and found that cytosolic Bax levels decreased at 
endstages of the disease (Fig 1.8B), while mitochondrial levels of Bax increased 
at endstages (Guegen et al, 2001) (Fig 1.8C). Since Bax is known to localize to 
the mitochondria in order to permeabilize the outer membrane to initiate 
apoptosis, this evidence supports an active role of Bax in apoptosis in an ALS 
mouse model. In addition other groups have shown this effect through a 
decreased ratio of anti apoptotic factors/Bax in ALS transgenic lines (Ekegren et 
al, 1999; Gonzalez et al, 2000). 
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All of these results were established in an SOD1G93A transgenic mouse 
model, but it should be noted that Bax levels have also been shown to increase 
and anti apoptotic factors shown to decrease at endstages of the disease in other 
mutant SOD1 transgenic animals, such as the SOD1G86R mouse model of ALS 
Fig 1.7 The role of anti-apoptotic factors in a mouse model of ALS. A) The 
age of onset is delayed and B) survival extended in a SOD1G93A/bcl-2 
overexpressing (triangles) animal vs. SOD1G93A/- (circles) animal (Kostic et al, 
1997). C) Endogenous levels of anti-apoptotic factors such as Bcl-2 and Bcl-xL 
are reduced at endstages of the disease compared to asymptomatic and non-
transgenic animals (Vukosavic et al, 2000). 
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(Gonzalez et al, 2000). The strongest evidence for Bax involvement in ALS is 
seen through a genetic deletion of Bax in the SOD1G93A mouse line. SOD1/Bax 
KO animals show a small extension in survival (Fig 1.8D) and better motor 
performance on the rotorod (Fig 1.8E) (Gould et al, 2006). 
Fig 1.8 The role of Bax in an SOD1G93A mouse model of ALS. A) Endogenous 
levels of Bax increase at endstage of the disease compared to asymptomatic and 
non-transgenic animals. Further characterization of Bax expression shows that 
B) cytosolic Bax decreases at endstage while C) mitochondrial Bax expression
increases. A genetic deletion of Bax in a SOD1G93A mouse model of ALS 
(triangles) compared to Bax WT (squares) shows a D) 20 day extension in 
lifespan and E) increased motor performance on the rotorod. AS = 





(Vukosavic et al, 1999: panel A; Guegen et al, 2001: panel B, C; Gould et al, 
2006: panel D, E) 
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In addition to these upstream apoptotic factors, there is also evidence for 
involvement of execution components of the apoptotic pathway. As mentioned 
above, Bax/Bak colocalization at the mitochondria causes permeabilization of its 
outer membrane, thus resulting in release of cytochrome c. At endstage (ES) of 
an SOD1G93A mouse model, cytochrome c is shown to shift from the mitochondria 
to the cytosol (Fig 1.9A) (Guegen et al, 2001). Evidence from other groups has 
shown that minocycline (an inhibitor of cytochrome c release) is able to delay 
progression of ALS (Zhu et al, 2002). Cytochrome c release allows for the 
activation of the apoptosome and subsequent cleavage and activation of the 
initiator caspase, Caspase-9. At endstages in ALS mice, cleavage of 
Procaspase-9 to its catalytically active form is observed (Fig 1.9C) (Guegen et al, 
2002). 
Downstream effector caspases, caspase-3 and caspase-7 are then 
subsequently cleaved at late stages of the disease (Fig 1.9D&E) (Li et al, 2000, 
Guegen et al, 2001). Lastly, a known inhibitor of caspases, XIAP has been 
shown to be cleaved to its inactive form at late stages of the disease (Fig 1.9B) 
(Guegen et al, 2001). XIAP is the most potent inhibitor of apoptosis found in the 
IAP family (Deveraux and Reed, 1999) and has been implicated in other 
neurodegenerative diseases (Xu et al, 1999). Together, these results provide 
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strong evidence for the role of the apoptotic pathway in transgenic mouse models 
of ALS. 
Fig 1.9 Evidence for involvement of downstream executors of apoptosis in 
ALS mouse models. A) Evidence of increased cytosolic cytochrome c and 
decreased mitochondrial cytochrome c at endstage of the disease. B) Cleavage 
of XIAP, a potent inhibitor of apoptosis, into its inactive form at endstages of the 
disease. C) Activation from inactive procaspase-9 to the catalytically active form 
of caspase-9 at endstages of the disease. D) Cleavage of Caspase-3 and E) 
Caspase-7 at symptomatic stages of the disease. AS = asymptomatic, BS = 
Beginning of symptoms, ES = End-stage, Non-Tg = Non-trangenic animals M = 







It should be mentioned that although multiple apoptotic downstream 
factors have been implicated in ALS through expression analysis, no follow up 
experiments deleting these genes in SOD1 mutant mouse models have been 
published. Studies with administration of zVAD-fmk, a broad caspase inhibitor, 
have shown delayed onset and extended survival in a mutant SOD1 mouse 
model (Li et al, 2000), but there has been concern in the field whether this 
inhibitor exhibits off-target effects. The only concrete evidence for endogenous 
levels of apoptotic factors extending lifespan is the study deleting Bax in the 
mutant SOD-1 trangenic line. Therefore, it is worth taking an in depth look at the 
parameters examined in the Bax knockout of the SOD-1 transgenic animal. 
Anatomical features of Bax deletion in the SOD1G93A mouse model 
Current evidence in the field suggests that the apoptotic pathway is 
involved in disease onset and progression of the SOD-1G93A ALS mouse model, 
with deletion of Bax having the most dramatic effect in delaying disease onset 
and extending lifespan. While knowledge that the apoptotic pathway plays a role 
in progression of the disease is useful, it is also important to understand its role in 
motor neuron degeneration at the anatomical level. 
The main insight from this study is that the Bax KO/SOD1G93A transgenic 
mouse line exhibits no reduction in motor neuron number at endstages of the 
disease (Fig 1.10A, B), but axon degeneration is similar to that seen to the 
SOD1G93A mouse model (Fig 1.10D, E) (Gould et al, 2006). It should be noted 
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that both the motor neuron cell body somal size (Fig 1.10C) and axon diameter at 
endstage (Fig 1.10F) were reduced in size. Gould et al concluded in this study 
that while blocking the apoptotic pathway in this mouse model was able to rescue 
motor neuron cell body loss, it was unable to rescue fibers from axon 
degeneration. It is unclear whether the extension in lifespan was actually due to 
the preserved cell body number at endstages of the disease or rather a delay in 
axon degeneration. 
Figure 1.10 Anatomical features of the SOD-1G93A/Bax KO mouse line. A) 
Representative images of motor neurons by vCHAT mRNA staining at P140 and 
Endstage in a Bax WT and Bax KO (top row) and SOD-1 Tg/Bax WT and SOD-1 
Tg/Bax KO (bottom row). Quantification of the B) number of lumbar motor 
A B C
D E F
neurons and C) somal size of the motor neurons pictured in A. D) Representative 
images of the ventral root in a Bax WT and Bax KO (top row) and SOD-1 Tg/Bax 
WT and SOD-1 Tg/Bax KO (bottom row) with quantification of E) axon number 
and F) axon diameter (Gould et al, 2006). 
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While there is strong evidence for a role of the apoptotic pathway in ALS 
mouse models, it is clear that ablating the apoptotic pathway is not sufficient to 
prevent disease. All manipulations of the apoptotic pathway have merely delayed 
onset and extended lifespan. Therefore, pathways other than apoptosis are likely 
to be involved in ALS. This is not surprising, especially due to the lack of 
apoptotic morphology of motor neurons seen in ALS patients and mouse models. 
Careful studies have tracked the progression of anatomical features of the 
disease as discussed above. It is therefore known that neuromuscular junction 
denervation and axon degeneration precede motor neuron cell body loss (Fischer 
et al, 2004) and that ablating the apoptotic pathway by a Bax deletion does not 
affect axon degeneration. We therefore, hypothesized that other molecular 
pathways that may play a role in neuromuscular junction denervation or axon 
degeneration would make good candidates to pursue in this ALS mouse model. 
The Wallerian degeneration pathway 
The Wallerian degeneration pathway seemed a perfect candidate for two 
reasons: (1) it is known to be independent of the apoptotic pathway (Whitmore et 
al, 2003) and (2) it is known to play a role in axon degeneration in other motor 
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neuron axonopathies (Ferri et al, 2003). Augustus Waller discovered Wallerian 
degeneration in 1850 as a process where the distal portion of the axon 
degenerates after insult or injury (Waller et al, 1850). The fortuitous generation of 
the Wallerian degeneration slow (WldS) mouse helped elucidate this pathway as 
an active degeneration process. In the WldS mouse, the distal axons that 
normally degenerate, remain intact for up to two weeks after being severed away 
from the cell body (Lunn et al, 1989, Tsao et al 1994). 
The WldS gene has been shown to protect axons in many disease models 
such as glaucoma, peripheral neuropathy, and motor neuron disease (Beirowski 
et al, 2008; Ferri et al, 2003; Hasbani and O’Malley, 2006; Mi et al 2005; Sajadi 
et al, 2004; Wang et al, 2002), but the role of WldS in ALS is unclear. Fischer et al 
found that when the WldS mouse was crossed with the SOD1G93A mouse model, 
there was increased survival compared to the SOD1G93A line (Fischer et al, 
2005). However, Vande Velde et al, did not see any difference in survival in the 
WldS/SOD1G37R or WldS/SOD1G85R mouse lines (Fig 1.11) (Vande Velde et al, 
2004). It is unclear whether these conflicting results are due to the difference in 
mutant SOD-1 transgenic lines tested, or whether there is ultimately no effect 
caused by the WldS fusion protein.  
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Figure 1.11 Conflicting results for the role of WldS in ALS. A) WldS/SOD1G93A 
mice show increased survival compared to the SOD1G93A line. B) No extension in 
survival is seen in WldS/SOD1G37R or C) WldS/SOD1G85R mouse lines. (Fischer et 
al, 2005: panel A; Vande Velde et al, 2004: panel B, C). 
The WldS gene encodes a chimeric fusion protein made up of the NAD 
biosynthetic enzyme nicotinamide mononucleotide adenyl-transferase (Nmnat1), 
which converts NAD+ from nicotinamide mononucleotide (NMN) and ATP, and a 
fragment of the ubiquitination factor UBE4B (Conforti et al, 2000). The WldS
fusion protein allows for localization of nuclear Nmnat1 to the axon, and this has 




2010; Sasaki et al, 2009). This has been verified with direct transduction of 
Nmnat1 protein into cut axons in vitro (Sasaki and Milbrandt, 2010) that can 
rescue axon degeneration and resulting axon degeneration after depletion of 
WldS protein from injured axons (Wang et al, 2015).  
It is thought that Nmnat1 has its axon protective effect by substituting for 
Nmnat2, which is normally present in the axon. Nmnat2 is supplied to the axon 
by continual axonal transport and thus, is blocked after injury. While the function 
of Nmnat2 in protecting axons after injury is not well understood, it is thought to 
function as a “survival factor” where its removal leads to axon degeneration, in 
uninjured or injured axons (Giley and Coleman, 2010). 
Ultimately, the WldS fusion protein present in the mouse confers a gain-of 
function process, overexpressing Nmnat1 in the axons of these animals. In 
addition to this caveat, the protective effect of the WldS allele against Wallerian 
degeneration is known to diminish with age (Gillingwater et al, 2002). For these 
reasons, the WldS mouse model is not an ideal model for assessing the role of 
Wallerian degeneration in ALS. 
Multiple studies have followed up on the initial WldS result to try and 
elucidate the mechanism of axon protection. A role for a new component in the 
Wallerian degeneration pathway came from a genetic screen in Drosophila. A 
mutation in dSarm showed delay in degeneration after axotomy of the olfactory 
receptor neuron axons (Osterloh et al, 2012). Jing Yang, a post doc in our lab, 
also showed that Sarm1 KO protected cortical and sensory axons from 
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degeneration after injury in vitro. He also demonstrated that Sarm1 KO axons 
were protected from NMJ denervation and axon degeneration after sciatic nerve 
crush in vivo (Fig 1.12) (Osterloh et al, 2012). 
Fig 1.12 Sarm1 KO protects against axon degeneration and NMJ 
denervation. A) Sarm1 KO (bottom row) protects against axon degeneration 
fourteen days after sciatic nerve crush (right two panels) compared to 
degenerated axon in Sarm1 heterozygotes (top row). No axon degeneration is 
seen in control uncut axons (left two panels). B) Sarm1 KO (bottom row) protects 
against muscle denervation six days after sciatic nerve crush (right two panels) 
compared to complete denervation in Sarm1 heterozygotes (top row). No NMJ 
denervation is seen in control uncut axons (left two panels) (Osterloh et al, 2012). 
We decided to address whether deletion of Sarm1 could protect against 
axon degeneration in an ALS mouse model for several reasons. 1) Sarm1 was 
identified to be an active executioner of Wallerian degeneration and and 2) 
because the WldS mouse involves a gain-of-function mutation and is not an ideal 
A B 
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model for studying the role of Wallerian degeneration as the protective effect of 
the WldS allele against Wallerian degeneration diminishes with age (Gillingwater 
et al, 2002). 
Perspective and overview of thesis project 
The overall goal of this project was to determine 1) the role of the 
Wallerian degeneration pathway and 2) its interaction with the apoptotic pathway 
in a mouse model of ALS. Establishment and characterization of a mouse model 
overexpressing a mutant gene, SOD-1G93A, originally identified to cause familial 
ALS in human patients, has allowed for a deeper investigation into the molecular 
mechanisms governing ALS. Careful examination of this mouse model led to the 
discovery of ALS as a ‘dying back’ axonopathy with neuronal distal regions such 
as the NMJ and axon preceding the effect seen at the cell body. 
The apoptotic pathway has already been identified to be involved in 
disease onset, progression, and survival in an SOD1G93A mouse model of ALS 
and was shown specifically to prevent motor neuronal cell body death, but had no 
effect on axon degeneration. This led us to investigate other players that were 
involved in NMJ denervation and axon degeneration, initial events in ALS. The 
Wallerian degeneration pathway served as a great candidate since it already was 
shown to be involved in other motor neuron diseases, had an effect on axon 
degeneration and NMJ denervation after sciatic nerve crush, and is independent 
of the apoptotic pathway. Initial experiments done in the lab knocking out Sarm1 
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in an SOD1G93A mouse model showed no effect on survival, but did show a 
difference in disease onset and progression of the disease (Fig 1.13). 
Figure 1.13 SOD-1G93A Tg, Sarm1-/- has effect on disease progression, but 
no effect on survival. A) Survival curve and B) disease progression of SOD-
1G93A Tg,Sarm+/+(black), SOD-1G93A Tg,Sarm+/-(blue) and, SOD-1G93A Tg,Sarm-/-
(red). Mice are given neurological score 2 when the hind limbs start to become 
paralyzed (Data from Jing Yang). 
Since Sarm1-/- animals did affect disease onset and progression in the 
SOD1G93A mouse, we next wanted to analyze the effect Sarm1 was having on the 
anatomical features of the disease. This project will explore the Sarm1-/- effect on 
neuromuscular junction denervation, axon degeneration, and motor neuron cell 
body death throughout disease progression. In addition to a closer histological 
analysis of the SOD-1G93A Tg,Sarm1-/- phenotype, we also wanted to explore the 
A B 
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interaction between this pathway and the classical apoptotic pathway, an already 
known regulator of disease progression and survival of the SOD1G93A mouse 
model of ALS. 
In Chapter 2, I will discuss the findings of disease onset, progression and 
survival when blocking individually the apoptotic pathway and the Wallerian 
degeneration pathway. I will then present the results of ablating both of these 
pathways together, specifically in the SOD-1G93A Tg mouse model. We identified 
that these pathways play distinct roles in disease onset and progression of the 
disease and that they act additively to reduce symptomatic stages of the disease. 
Chapter 3 explores the anatomical features of deleting each of these 
pathways individually and in combination. Histology was performed to examine 
neuromuscular junction denervation in different hindlimb muscles, motor axon 
degeneration in the ventral root, and cell body loss in the spinal cord. The 
histological results track closely with progression of the disease in the ALS 
mouse model. I conclude with a discussion tying the disease progression and 
histology results together. 
Chapter 4 investigates the non-cell autonomous role that is thought to 
occur in the mutant SOD-1 mouse model of ALS. Examination of this non-cell 
autonomous effect is pursued through the in vitro approaches described 
previously, specifically using SOD-1 Tg astrocyte conditioned medium and 
microglial co-cultures with primary motor neurons to identify new factors and 
elucidate more fully the role of the Wallerian degeneration pathway in motor 
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neuron cell death. I conclude with a discussion of these results and suggestions 
for future experiments. 
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Chapter 2: Apoptosis and Wallerian degeneration affect 
disease onset and progression 
Rationale 
Previous studies showed that deletion of apoptotic pathway components 
slows disease progression in the SOD-1G93A Tg mouse model of ALS, specifically 
exerting its effect on motor neuron cell bodies and not axon degeneration. This 
led us to explore other potential pathways that might mediate axon degeneration 
in this disease model, particularly the Wallerian degeneration pathway. We 
further wanted to examine the interaction between these two pathways to 
determine if they could act synergistically to affect disease. 
To determine the role of these two pathways both individually and 
together, we decided to track disease onset and progression closely through 
daily monitoring of disease symptoms through a neurological scoring system. 
This allowed us to resolve the individual role of each of these pathways in the 
behavioral phenotype exhibited by these mice. 
Bax, but not Sarm1 deletion extends survival of the SOD-1G93A Tg mouse 
model 
To determine the individual and collaborative roles of the Wallerian 
degeneration and the classical apoptotic pathways in ALS, we assessed the 
effects of Sarm1 and Bax on survival and disease progression in SOD-1G93A Tg 
mice. We first tested SOD-1 copy number in all of the SOD-1 Tg animals and 
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removed all animals out of the range of the recommended SOD-1 copy number 
used by standard Jackson Laboratory protocols (Fig 2.1). 
 
 
Figure 2.1 SOD-1G93A copy number analyzed by qPCR. SOD-1G93A Tg animals 
were tested for transgene copy number using quantitative PCR. Four mice were 
excluded from the analysis (indicated in red boxes) since they exhibited SOD-1 
copy number outside the range of those allowed by Jackson mice protocol 
standards. 
Consistent with previous results, blocking the apoptotic pathway by 
genetic deletion of Bax prolongs survival of SOD-1G93A Tg mice by ~20 days 
compared to littermate controls (SOD-1G93A,Bax-/-:187 +/- 13 days ; SOD-
1G93A,Bax+/+: 168 days +/- 14 days , **p =0.0052). Blocking both the Wallerian 
Mouse number 


























degeneration and apoptotic pathways similarly extended lifespan, but offered no 
additional extension over genetic deletion of Bax alone (SOD-1G93A,Bax-/-;Sarm1-/-
: 182 +/- 14 days; *p =0.0495). No effect on survival was observed in mice 
lacking Sarm1-/- alone (SOD-1G93A,Sarm1-/-: 172 +/- 12 days, SOD-
1G93A,Sarm1+/+: 168 +/- 14 days). (Fig 2.2A).  
Interestingly, body weight loss was significantly delayed in SOD-1G93A
Tg,Bax-/-;Sarm1-/- mice compared to SOD-1G93A Tg (SOD-1G93A: 156 days +/- 13 
days,  SOD-1G93A,Bax-/-:170 +/- 14 days; ***p =0.0006, SOD-1G93A,Bax-/-;Sarm1-/-: 
182 +/- 14 days; ***p =0.0004) and SOD-1G93A Tg ,Bax-/- mice (*p=0.0435), 
indicating that SOD-1G93A Tg,Bax-/-;Sarm1-/- animals are healthier for a longer 
period of time, despite the fact that their lifespan is not extended relative to SOD-
1G93A Tg lacking only Bax-/- (Fig 2.2B). 
Figure 2.2. Survival and body weight loss of SOD-1G93A Tg mice. (A) Survival 
and (B) body weight loss of SOD-1G93A Tg (black), SOD-1G93A Tg,Bax-/-
Sarm+/+(blue), SOD-1G93A Tg,Bax+/+Sarm-/-(red), and SOD-1G93A Tg,Bax-/-Sarm-/- 
(green). This color scheme will be used throughout all of the figures in this paper.  
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In addition to tracking survival and body weight, we also performed a 
rotorod behavioral assay to assess motor performance of these animals. We 
performed the rotorod assay on a different cohort of animals because exercise is 
known to affect disease onset and progression. Since the size of this cohort was 
so large, we needed to modify the existing rotorod protocol in order to test all of 
the mice. The rotorod behavioral assay is normally performed every other day for 
the duration of the study. We decided to test each mouse monthly at different 
timepoints including P50, P90, P120, P150, and P180. These timepoints included 
asymptomatic, early stage symptomatic, and late stage symptomatic periods. We 
needed to test how much training was necessary to achieve results that related 
to motor function and not motor learning. 
In order to do this, we had differently staged mice perform three days of 
training on the rotorod. We also slightly modified the rotorod protocol so that mice 
were exposed to a short training period before times were recorded. Our results 
showed that while training on the rotorod did slightly increase overall time the 
mice were able to stay on the rotorod, the significant decrease in time at late 
stages was observed similarly after either one, two, or three days of training 
(Figure 2.3A-C). This allowed us to use this newly developed protocol to measure 
differences seen between genotypes. Unfortunately, we were unable to 
distinguish a difference among genotypes (Fig 2.3D), most likely because the 
timepoints at which the mice were tested were too far apart to catch any key 
differences. 
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Figure 2.3. Rotorod Behavioral Assay. A new training protocol was 
developed to test the rotorod behavioral assay in mice. Mice at different ages and 
disease stages were tested using this new protocol with A) 1 day of training, B) 2 
days of training, or C) 3 days of training. The age of the mice and neurological 
score is listed on the x-axis of the graph. S0 = Score 0, S1 = Score 1, ES2 = 
early stage 2, S3 = Stage 3, LS2 = late stage 2. D) Rotorod performance of SOD-
1G93A Tg (black solid line), SOD-1G93A Tg,Bax-/-Sarm+/+(blue solid line), SOD-1G93A 
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SOD-1WT (black dotted line) SOD-1WT,Bax-/-Sarm+/+ (blue dotted line), SOD- 
1WT,Bax+/+Sarm-/- (red dotted line) and SOD-1WT,Bax-/-Sarm-/- (green dotted line) 
animals at P50 (n=15 per genotype), P90 (n=12 per genotype), P120 (n=9 per 
genotype), P150 (n = 6 per genotype) and P180 (n = 3 per genotype). 
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Sarm1 involved in early stages and Bax involved in late stages of the 
disease 
Neurological scoring system guidelines from The Jackson Laboratory were 
used to track symptom onset and disease progression in mice (Fig 2.4A). SOD-
1G93A Tg,Bax-/- and SOD-1G93A Tg,Bax-/-;Sarm1-/- mice remained symptom free for 
significantly longer than SOD-1G93A Tg controls (SOD-1G93A: 143.8 +/- 5.26; SOD-
1G93A,Bax-/-:159.2+/-5.5 days, *p =0.0291; SOD-1G93A,Bax-/-, Sarm1-/-: 171.1+/- 
4.91; **p =0.0016).  Although Sarm1-/- does not prolong survival of SOD-1G93A Tg 
ALS animals, disease onset and progression were modestly affected. SOD-1G93A
Tg, Sarm1-/- animals exhibit disease-associated symptoms (score 1: muscle 
weakness) earlier than littermate controls (SOD-1G93A,Sarm1-/-: 132.8 +/- 7.74 
days). (Fig 2.4B). However, progression to score 2 is delayed, thereby prolonging 
the period that SOD-1G93A Tg, Sarm1-/- animals exhibit early disease symptoms 
compared to SOD-1G93A Tg animals (SOD-1G93A: 18.33 +/- 3.091 days; SOD-
1G93A,Sarm1-/-: 37.55 +/- 7.056 days, * p =0.033). In contrast, progression from 
score 1 to score 2 occurs more quickly in SOD-1G93A Tg, Bax-/-; Sarm1-/- animals 
(SOD-1G93A Tg, Bax-/-; Sarm1-/- : 8 +/- 1.462 days, ** p =0.008)  (Fig 2.4C). 
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Genetic disruption of the Wallerian and apoptotic pathways also modifies 
later stages of the disease. In SOD-1G93A Tg, Bax-/- mice, the length of time 
between onset of score 2 to paralysis (ES) is significantly prolonged compared to 
controls (SOD-1G93A: 6.56 +/- 1.69 days; SOD-1G93A,Bax-/-:12.91 +/- 1.84 days; 
*p=0.022) (Fig 2.4D).
Figure 2.4 Disease onset and progression of SOD-1G93A Tg mice. (A) 
Schematic of neurological scoring and corresponding disease stage of animal. 
Mean number of days mice in each genotype (SOD-1G93A Tg (n=9), SOD-1G93A 
Tg,Bax-/-Sarm+/+(n=11), SOD-1G93A Tg,Bax+/+Sarm-/-(n=9), and SOD-1G93A 
Tg,Bax-/-Sarm-/-(n=9)) listed above was given score 0 and termed 
presymptomatic (B), given score 1 and termed as early stage (C), and given 




Elimination of both Bax and Sarm decreases symptomatic stages in ALS 
Further, total disease duration was significantly reduced in the SOD-1G93A
Tg, Bax-/-;Sarm1-/- animals relative to other groups (SOD-1G93A: 26.67 +/- 3.44 
days, SOD-1G93A Tg, Bax-/-, 26.90 +/- 4.829 days, ; SOD-1G93A,Sarm1-/-: 41.55 +/- 
7.91 days SOD-1G93A,Bax-/-, Sarm1-/-: 13.56 +/- 2.28 days; *p =0.017, *p =0.029, 
**p =0.002, respectively) (Fig 2.5A). The differences in disease progression that 
are observed between Bax-/- and Sarm1-/- animals indicate that the apoptotic and 
Wallerian degeneration pathways play parallel and synergistic roles in ALS (Fig 
2.5B). 
Figure 2.5 Duration and complete progression of SOD-1G93A Tg mice.  (A) 
Mean number of days spent in both early and late stage of disease which results 
in total duration of symptomatic stages of the disease (B) Mean number of days 




Here we showed that the apoptotic pathway and Wallerian degeneration 
pathway play distinct roles in disease onset and progression of the disease. By 
tracking disease symptoms, we were able to show that the Wallerian 
degeneration pathway through deletion of Sarm1 plays a role in symptom onset 
of the disease, while the apoptotic pathway is involved more in late stages of the 
disease. We also were able to show that the apoptotic pathway can delay 
symptom onset, but does not decrease overall duration of the disease, whereas 
deletion of Sarm1 does increase overall disease. 
Interestingly, the neurological scoring and body weight loss results show 
that the apoptotic and Wallerian degeneration pathways function additively to 
control disease onset and progression, ultimately resulting in a decreased burden 
of symptomatic stages of the disease and an extended survival that is 
comparable to the individual deletion of the apoptotic pathway. 
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Chapter 3: Histological analysis tracks with disease 
Rationale 
Since the Bax and Sarm genes were found to play distinct roles in disease 
onset and progression, we next wanted to ask what the anatomical features 
throughout disease progression were when deleting these genes, both 
individually and together. We also wanted to determine how these histological 
changes tracked with disease onset and progression. 
Along with a general characterization of anatomical features throughout 
the disease, we also were curious to investigate the role of each of these 
pathways in the “dying back” progression of the disease. Previous results had 
shown that deleting the apoptotic pathway resulted in preserved motor neuron 
cell body loss, but no axon degeneration at endstages of the disease. We wanted 
to perform a closer analysis at various timepoints to determine if this delayed 
onset tracked with delayed early features of the disease, such as NMJ 
denervation and axon degeneration. Furthermore, this is the first study to perform 
careful histological characterization when deleting the Wallerian degeneration 
pathway and with double deletion of both pathways. 
Bax and Sarm1 play distinct roles in neuromuscular junction denervation 
To determine how the Wallerian and apoptotic pathways affect 
neuromuscular junction denervation in the SOD-1G93A Tg model of ALS, 
gastrocnemius and tibialis anterior muscles were examined at different disease 
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stages. Representative images are shown for the tibialis anterior (Fig 3.1) and 
the gastrocnemius muscle (Fig 3.2). In SOD-1G93A Tg animals, NMJ denervation 
was first observed at P90 and was nearly complete by disease endstage (Fig 3.1, 
3.2, quantified in 3.3). Denervation of both muscles was significantly delayed at 
P90 in both SOD-1G93A, Bax-/- and SOD-1G93A, Bax-/-, Sarm1-/- (Fig 3.1, 3.2, 3.3), 
but only the tibialis anterior muscle showed delayed NMJ denervation in the 
SOD-1G93A, Sarm1-/- mice at P90 (SOD-1G93A: 39.67 +/- 6.36 % innervated,  
SOD-1G93A,Bax-/-: 100 +/- 0; ***p<.0001, SOD-1G93A, Sarm1-/-: 92.33 +/- 4.09, 
***p<0.001; SOD-1G93A,Bax-/-, Sarm1-/-: 100 +/- 0; ***p<0.001 for tibialis anterior 
and SOD-1G93A: 45 +/- 8.62 % innervated,  SOD-1G93A,Bax-/-: 100 +/- 0; 
***p<.0001, SOD-1G93A, Sarm1-/-: 37.33 +/- 1.202; SOD-1G93A,Bax-/-, Sarm1-/-: 100 
+/- 0; ***p<0.001 for gastrocnemius). 
At P120 and P150, the percentages of partially and completed denervated 
NMJs were similar across all the genotypes for the gastrocnemius muscle (Fig 
3.2, quantified in 3.3B). However, in the tibialis anterior, the number of fully 
innervated NMJs was significantly increased in SOD-1G93A,Bax-/-, Sarm1-/- mice 
compared to the SOD-1G93A Tg at P120 and P150 (Fig 3.1, 3.3A) (SOD-1G93A: 
21.33 +/- 13.74 % innervated, SOD-1G93A,Bax-/-, Sarm1-/-: 53 +/- 0.58 at P120 and 
SOD-1G93A: 13.67 +/- 0.89  % innervated, SOD-1G93A,Bax-/-, Sarm1-/-: 36.33 +/- 
6.64 at P150). 
In P90 SOD-1G93A; Sarm1-/- mice, NMJ innervation is preserved in the 
tibialis anterior, but not the gastrocnemius muscle. Increased NMJ innervation 
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was also observed in the SOD-1G93A,Bax-/-, Sarm1-/- tibialis at later time points 
(P120 and P150). Denervation was decreased in SOD-1G93A,Bax-/-, Sarm1-/- 
gastrocnemius muscle relative to the SOD-1G93A Tg, but the reduction was not 
significant (Fig 3.2 and quantified in 3.3B). 
Figure 3.1 Neuromuscular junction denervation of the tibialis anterior 
muscle throughout disease progression. α-bungarotoxin was used to label 
postsynaptic sites (green) and synapsin antibody (red) labeled presynaptic sites 
of the neuromuscular junction in the tibialis anterior (shown above). Yellow was 
counted as completely innervated synapses, yellow and green (indicated by 
white arrows) were counted as partially innervated synapses, and green only 
were counted as denervated synapses. (A) SOD-1G93A Tg, (B) SOD-1G93A 
Tg,Bax-/-Sarm+/+, (C) SOD-1G93A Tg,Bax+/+Sarm-/-, and (D) SOD-1G93A Tg,Bax-/-
Sarm-/- animals (n=3 for each timepoint) were dissected when each reached P50, 
P90, P120, P150, and when they reached score 4, or endstage. Scale bar = 20 
μm. 
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Figure 3.2 Neuromuscular junction denervation of the gastrocnemius 
muscle throughout disease progression. α-bungarotoxin was used to label 
postsynaptic sites (green) and synapsin antibody (red) labeled presynaptic sites 
of the neuromuscular junction in the gastrocnemius muscle. Yellow was counted 
as completely innervated synapses, yellow and green (indicated by white arrows) 
were counted as partially innervated synapses, and green only were counted as 
denervated synapses. (A) SOD-1G93A Tg, (B) SOD-1G93A Tg,Bax-/-Sarm+/+, (C) 
SOD-1G93A Tg,Bax+/+Sarm-/-, and (D) SOD-1G93A Tg,Bax-/-Sarm-/- animals (n=3 for 
each timepoint) were dissected when each reached P50, P90, P120, P150, and 
when they reached score 4, or endstage. 
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Figure 3.3 Neuromuscular junction quantification of the tibialis anterior and 
gastrocnemius muscle. Synapses from Fig 3.1 and 3.2 were quantified as 
either innervated (yellow bars), partially innervated (grey bars) or denervated 
(green bars) in the (A) tibialis anterior and (B) gastrocnemius in the SOD-1G93A 
Tg (black font) SOD-1G93A Tg,Bax-/-Sarm+/+ (blue font), SOD-1G93A Tg,Bax+/+Sarm-
/-(red font), and SOD-1G93A Tg,Bax-/-Sarm-/- (green font) animals (n=3 for each 
timepoint) at P50, P90, P120, P150, and ES (endstage). 
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Sarm1 deletion slightly delays axon degeneration in SOD-1G93A Tg 
animals 
Ventral root samples were analyzed to determine the effect of the 
apoptotic and Wallerian degeneration pathways on axon degeneration. The 
number of large and small diameter axons that were intact or degenerated was 
quantified at different time points throughout the disease (Fig 3.4 and quantified 
in 3.5). Large diameter axons first showed signs of degeneration by P120 in 
SOD-1G93A controls, with a significant decrease in the number of intact axons by 
P150 (Fig 3.5A). In SOD-1G93A,Bax-/-, Sarm1-/- mice, axon degeneration was 
significantly delayed, as evidenced by an increase in the number of large 
diameter axons at P150 (SOD-1G93A: 42.25 +/- 23.9 large axons, SOD-1G93A,Bax-
/-, Sarm1-/-: 161.3 +/- 12.1 at P150; *p=0.03) (Fig 3.5A). Degeneration was also 
modestly affected in SOD-1G93A,Bax-/- and SOD-1G93A, Sarm1-/- , but not 
significantly. 
By disease endstage, axons had degenerated to a similar extent across 
genotypes. Consistent with a role for Bax in developmental cell death, the 
number of small diameter axons was significantly increased in SOD-1G93A,Bax-/- 
mice, and to a similar extent in SOD-1G93A,Bax-/-;Sarm1-/- animals at all ages. The 
number of small diameter axons was modestly affected at disease endstage in all 
mutants, but significantly in both SOD-1G93A,Bax-/- and SOD-1G93A,Bax-/-;Sarm1-/-
mice (Fig 3.5B). These results indicate that loss of motor axons in the ventral root 
mostly reflects the loss of large diameter axons. 
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Figure 3.4. Motor axon degeneration in ventral root. Representative electron 
micrograph images taken of ventral root samples dissected from (A) SOD-1G93A 
Tg, (B) SOD-1G93A Tg,Bax-/-Sarm+/+, (C) SOD-1G93A Tg,Bax+/+Sarm-/-, and (D) 
SOD-1G93A Tg,Bax-/-Sarm-/- animals (n=3 for each timepoint) when each reached 
P50, P90, P120, P150, and when they reached score 4, or endstage. Black 
arrows indicate large degenerating axons. Scale bar = 5 μm. 
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Figure 3.5. Quantification of large and small axons in ventral root. Intact 
(black bars) and degenerated (gray bars) (A) large and (B) small diameter axons 
were counted from SOD-1G93A Tg (black font) SOD-1G93A Tg;Bax-/-Sarm+/+ (blue 
font), SOD-1G93A Tg;Bax+/+Sarm-/-(red font), and SOD-1G93A Tg;Bax-/-Sarm-/- 
(green font) animals (n=3 for each timepoint) at P50, P90, P120, P150, and ES 
(endstage). 
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Deletion of Bax and Sarm1 delays large neuron loss in ventral horn 
NeuN+ cell bodies were counted in the ventral horn of the spinal cord. 
SOD-1G93A Tg animals first exhibit motor neuron loss at late stages (P150) and at 
endstage, after NMJ denervation and axon degeneration (Fig 3.6A, 3.6E) as 
reported (Fischer et al, 2004). As reported previously (Gould et al., 2006), the 
ventral horn of SOD-1G93A, Bax-/- animals show an increase in neuron number 
(SOD-1G93A: 50 +/- 1.0 NeuN+ neurons, SOD-1G93A,Bax-/-: 82.7 +/- 1.33 NeuN+ 
neurons at P50), reflecting both a lack of developmental neuronal cell death and 
protection of neuronal cell body death at disease endstage (SOD-1G93A,Bax-/-: 
82.7 +/- 1.33 NeuN+ neurons at P50,  SOD-1G93A,Bax-/-: 88.33 +/- 1.76 NeuN+ 
neurons at endstage (ES) p=ns) (Fig 3.6B and quantified in 3.6E). Large cell 
bodies in the ventral horn (>10μm in diameter), thought to be the more vulnerable 
neuron population in ALS, were also quantified. Although it was not statistically 
significant, a trend of large motor neuron loss was observed in the P150 SOD-
1G93A,Bax-/-mice (SOD-1G93A,Bax-/-: 27.7 +/- 1.20 large NeuN+ neurons at P50,  
SOD-1G93A,Bax-/-: 23 +/- 3.22 large NeuN+ neurons at P150). Loss of large 
neurons in SOD-1G93A,Bax-/- mice was comparable to the SOD-1G93A Tg mice at 
endstage (Fig 3.6) (SOD-1G93A: 14.33 +/- 0.33 large NeuN+ neurons at ES; SOD- 
1G93A,Bax-/-: 15.33 +/- 0.33 large NeuN+ neurons at ES). There was no change in 
total NeuN+ neuron number in SOD-1G93A,Bax-/- mice at endstage, because the 
supernumerary large neurons atrophied and became smaller. 
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Numbers of ventral horn neurons were similar in SOD-1G93A,Sarm1-/- mice 
and SOD-1G93A Tg animals at P50 (SOD-1G93A: 50 +/- 1.0 NeuN+ neurons; SOD-
1G93A,Sarm1-/-: 52.7 +/- 1.33 NeuN+ neurons) Ventral horn neuron loss (total 
NeuN+ neurons and large neurons (>10μm)) was delayed in P150 SOD-
1G93A,Sarm1-/- mice relative to SOD-1G93A Tg animals, but neuron loss was similar 
at endstage (Fig 3.6C, 3.6E, 3.6F) (SOD-1G93A: 34.33 +/- 4.096 NeuN+ neurons 
at P150; SOD-1G93A,Sarm1-/-: 51.7 +/- 0.33 NeuN+ neurons at P150; * p = 0.02; 
SOD-1G93A: 28.33 +/- 2.667 NeuN+ neurons at ES, SOD-1G93A,Sarm1-/-: 24.67 +/- 
1.33 NeuN+ neurons at ES, p=0.36). 
The last time point (endstage) was always measured when the animal 
reached Score 4 (complete paralysis) and varied among genotypes. The SOD-
1G93A and SOD-1G93A,Sarm1-/- animals reached this stage around P165, whereas 
the SOD-1G93A,Bax-/- and SOD-1G93A,Bax-/-;Sarm1-/- mice reached this stage 
around P185. Thus, Sarm1-/- protection of both large and total ventral horn 
neuron number at P150 is closer to the time when the animals reach Score 4, 
suggesting that deletion of Sarm1 causes the late stage of the disease to 
progress rapidly. This is consistent with the neurological scoring phenotype in 
which the SOD-1G93A,Sarm1-/- animals get the disease later (Score 2) and 
progress very rapidly to endstage (Fig 2.4B). 
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Figure 3.6. Neuron cell body loss in ventral horn of spinal cord. 
Representative images of NeuN+ stained 12 μm spinal cord sections labeling cell 
bodies in (A) SOD-1G93A Tg, (B) SOD-1G93A Tg,Bax-/-Sarm+/+, (C) SOD-1G93A 
Tg,Bax+/+Sarm-/-, and (D) SOD-1G93A Tg,Bax-/-Sarm-/- animals (n=3 for each 
timepoint) were dissected when each reached P50, P90, P120, P150, and when 
they reached score 4, or endstage. Yellow dotted line indicates ventral horn 
where cell bodies were counted and * indicates midline of spinal cord. 
Quantification of (E) total NeuN+ neurons and (F) large NeuN+ neurons (>10 μm) 
located in the ventral horn at timepoints listed above. Scale bar = 50 μm 
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Deletion of Bax and Sarm1 delays loss of MMP-9+ neurons 
MMP-9 is a marker for the type of large motor neurons most susceptible to 
degeneration in ALS (Kaplan et al, 2014). MMP-9+ expressing neurons in the 
SOD-1G93A animals degenerated at P120 (Fig 3.7A, quantified in 3.7E) (SOD-
1G93A: 4.65 +/- 0.43 MMP-9+ neurons at P50; SOD-1G93A: 2.08 +/- 0.63 MMP-9+ 
neurons at P120; * p = 0.05). Sarm1 knockout, and Bax;Sarm1 double knockout 
protected MMP-9+ expressing ventral horn neurons up to P150 (Fig 3.7B-D) ) 
(SOD-1G93A: 1.51 +/- 0.44 MMP-9+ neurons; SOD-1G93A,Bax-/-: 3.07 +/- 0.70; 
p=0.4 ; SOD-1G93A, Sarm1-/-: 3.28 +/- 0.06, *p=0.05; SOD-1G93A,Bax-/-, Sarm1-/-: 
4.13 +/- 0.13 ; *p=0.03 at P150). MMP-9+ expressing neurons were lost similarly 
in all genotypes at endstage (Fig 3.7E) (SOD-1G93A: 1.01 +/- 0.20 MMP-9+ 
neurons; SOD-1G93A,Bax-/-: 1.11 +/- 0.11; SOD-1G93A, Sarm1-/-: 1.00 +/- 0.17; 
SOD-1G93A,Bax-/-, Sarm1-/-: 1.34 +/- 0.21 ; at ES). 
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Fig 3.7. MMP-expressing neuron loss in the ventral horn of the spinal cord. 
Representative images of MMP-9+ stained 12 μm spinal cord sections labeling 
motor neuron cell bodies in (A) SOD-1G93A Tg, (B) SOD-1G93A Tg,Bax-/-Sarm+/+, 
(C) SOD-1G93A Tg,Bax+/+Sarm-/-, and (D) SOD-1G93A Tg,Bax-/-Sarm-/- animals (n=3 
for each timepoint) were dissected when each reached P50, P90, P120, P150, 
and when they reached score 4, or endstage (ES). P50 and P150 representative 
images are shown. (E) Quantification for MMP-9+ motor neurons in P50, P90, 
P120, P150, and ES ventral spinal cords. 
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Conclusions 
The results of histological analysis in Bax-/- and Sarm1-/- animals tracked 
closely with disease progression. Apoptotic and Wallerian degeneration 
pathways played distinct roles in the dying back phenotype. Symptom onset did 
not correlate strictly with the start of neuromuscular junction denervation, but 
rather occurred about thirty days after the start of NMJ denervation. However, 
delay in NMJ denervation did correlate with a delayed symptom onset. 
Interestingly, the SOD-1G93A,Bax-/-Sarm1-/- animals showed improved 
neuronal morphology phenotype in all parameters, including a delayed 
denervation at the NMJ, delayed axon degeneration, and motor neuron cell body 
preservation which aligned with a delayed symptom onset. These differences 
were even stronger even further than the Bax-/- strain alone. 
64 
Chapter 4: Non-cell autonomous SOD-1 toxicity 
Rationale 
In parallel with the in vivo studies described above, we also took an in vitro 
approach to identify novel factors that might play a role in SOD-1-mediated cell 
death and to elucidate further the mechanism of neuronal cell death observed in 
vivo. We attempted to replicate the previously reported co-culture assay of WT 
motor neurons and conditioned medium from mutant SOD-1 astrocytes. The goal 
of this project was to 1) screen through other factors of the apoptotic pathway to 
determine their role in motor neuron cell death and 2) elucidate further the 
mechanism between the apoptotic and Wallerian degeneration pathway in vitro.  
Co-culture of motor neurons and astrocytes 
In order to screen through other potential players that were involved in 
causing motor neuron cell death in this SOD-1-mediated toxicity assay, we 
needed to first replicate the assay. I first dissected motor neurons from the E12.5 
spinal cords of the Hb9-GFP mouse line and co-cultured them with astrocytes 
(Fig 4.1A). I then treated WT primary motor neurons with collected conditioned 
medium (CM) from either SOD-1G93A Tg astrocytes or Non-transgenic littermate 
controls (Ntg). After 7 days in culture, I observed a small decline in motor neuron 
number in cultures conditioned with SOD-1 Tg CM compared to Ntg conditioned 
medium (Fig 4.1B) 
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Fig 4.1 Motor neuron loss after treatment with SOD-1 astrocyte conditioned 
medium. A) Motor neurons isolated from the HB9-GFP mouse line stained with 
GFP (green) and HB9 antibody (red) co-cultured with an astrocyte monolayer, 
stained with the marker astrocyte-specific marker, GFAP (blue). B) Motor neuron 
number after 7 days cultured with either CM from non-transgenic Ntg astrocytes 
(white bar) or SOD-1G93A Tg astrocytes, MN = motor neuron (black bar).  
However, we found that not every Hb9-GFP expressing cell stained with 
the Hb9 antibody (Fig 4.2A). This led to an investigation of the Hb9-GFP line that 
we were using in the lab. Although Hb9 is a post mitotic marker of motor neurons, 
we had discovered the Hb9-GFP line was not specific to motor neurons both by 
observing E12.5 sections from spinal cord stained with Hb9 antibody and either 
stained with GFP antibody (Fig 4.2B) or just looking at endogenous GFP (Fig 

















MN loss after treatment 
with conditioned medium 
that labeled motor neurons more specifically was peripherin, which we showed 
successful labeling both in vivo (Fig 4.2E) and in vitro (Fig 4.2F). 
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Fig 4.2 Peripherin as a marker for motor neurons. A) Motor neurons 
dissected and dissociated from spinal cords at E12.5 from the Hb9-GFP mouse 
line. Circled motor neurons also labeled with the Hb9 antibody stain. B) 
Unspecific staining of non motor neurons of E12.5 spinal cords in the Hb9-GFP 
mouse line co-labeled with Hb9 and either GFP antibody (green) or C) 
endogenous GFP. Serial sections of E12.5 spinal cord stained with D) Hb9 and 
E) peripherin. F) Peripherin (green) and Tuj (red) staining in vitro.
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Non-cell autonomous SOD-1 toxicity causes motor neuron cell death, but 
not axon degeneration 
Once we determined a marker for motor neurons in vitro, we attempted to 
reproduce the SOD-1 Tg astrocyte-mediated toxicity of primary WT motor 
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neurons (Nagai et al, 2007). We collected conditioned medium (CM) from both 
SOD-1G93A Tg astrocytes and their nontransgenic littermate controls and placed 
the CM on dissociated motor neuron cultures for 7 days. We saw a decline of 
motor neuron number (i.e. peripherin+ neurons) conditioned with SOD-1G93A Tg 
CM compared to WT CM (Fig 4.3A-C). 
We next wanted to determine the effect of SOD-1G93A Tg CM on axon 
degeneration since deletion of Sarm1 slightly delayed axon degeneration in vivo. 
We utilized an assay using a spinal cord explant developed in the lab by Zhuhao 
Wu. The ventral section of the spinal cord was isolated and allowed to adhere to 
PDL/laminin coated cover slides. These explants grow their axons in a concentric 
fashion. We treated these ventral explants with either WT or SOD-1 Tg CM. We 
did not observe axon degeneration of the ventral explants cultured with SOD-1 
Tg CM compared to WT CM either after 2 days (Fig 4.3D-E) or 7 days (data not 
shown). 
We next tried to co-culture microglia with the ventral explant cultures since 
microglia were shown by others to cause more motor neuron death than either 
the SOD-1 Tg astrocyte monolayer or CM (Nagai et al, 2007). We isolated 
cortical microglia from P0 pups and allowed microglia to adhere for three to four 
days before plating ventral explant cultures. Ventral explant cultures were grown 
on microglia either isolated from SOD-1 Tg animals or littermate controls (WT) for 
seven days. Axons from ventral explant cultures did not show any difference in 
degeneration cultured with WT vs. SOD-1 Tg microglia (Fig 4.3 F & G). 
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Fig 4.3 Mutant SOD-1 CM causes motor neuron cell death in dissociated 
culture, but not ventral explant culture. Dissociated motor neurons labeled 
with tuj (red) and peripherin (green) treated with CM from A) WT astrocytes or B) 
SOD-1G93A Tg astrocytes. C) Quantification of motor neurons shows significant 
loss of motor neuron number cultured with SOD-1 CM compared to WT CM. No 
axon degeneration is seen in E12.5 ventral explants cultured with D) WT 
astrocyte CM vs. E) SOD-1 astrocyte CM. No axon degeneration is seen in E12.5 
ventral explants cultured with F) WT microglia vs. G) SOD-1 microglia. 
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While we were able to replicate the cell death phenotype attributed by 
SOD-1 Tg astrocyte conditioned medium, the effect was not robust enough to 
identify novel factors. We sought an enhanced phenotype in ventral explant 
cultures, specifically looking for an axon degeneration phenotype that we could 
study in vitro. We were unable to observe any effect of either SOD-1 Tg 
astrocyte-conditioned medium or microglia monolayers. These negative results 
could have been caused by a number of different factors. For example, 
astrocytes and microglia are not present in the peripheral nervous system and 
therefore direct contact with these factors might not effect axon degeneration; 
more natural sources of regulators would be Schwann cells. 
A	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Chapter 5: Discussion and Future Directions 
Before this study, there were conflicting reports as to the role of the 
Wallerian degeneration pathway in mouse models of ALS. By deleting an active 
executor of this pathway, Sarm1, we were able to definitively determine this 
pathway’s role in a mouse model of ALS. This study answers whether deleting 
the Wallerian degeneration pathway from the SOD-1G93A Tg mouse model would 
extend lifespan as previously seen in the WldS/SOD-1G93A Tg mouse (Fischer et 
al, 2004). We determined that knocking out Sarm1 and therefore ablating this 
pathway does not further extend lifespan in an SOD-1G93A mouse model. 
Therefore, the effect seen by WldS is likely caused by a gain of function 
independent of Sarm1. Through careful characterization, we determined that the 
Wallerian degeneration pathway plays a role in disease onset and progression. 
In this study we completed a deeper analysis than had been done 
previously on deleting the apoptotic pathway in the SOD-1G93A mouse model. We 
were able to reproduce the previously reported results of cell body preservation 
at endstage in the spinal cord, delayed neuromuscular junction denervation, and 
extended lifespan (Gould et al, 2006). In addition to these results, we showed a 
delayed onset in symptoms of the disease, a prolonged late stage of the disease, 
and a specific loss of large axon and cell bodies at endstage. 
This study is the first to show that deleting the Wallerian degeneration 
pathway and the apoptotic pathway together resulted in an additive phenotype, 
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more dramatic than deleting each of these pathways individually. We found 
further delayed onset of symptoms, which tracked with histological effects 
indicating delayed NMJ denervation, protection of axons at late stages of the 
disease, and preservation of cell bodies at endstage. Most interestingly, all of this 
resulted in a decreased duration of symptomatic stages of the disease. 
The role of Sarm1 in the SOD-1G93A Tg model of ALS 
In this study, we explored the role of the Wallerian degeneration pathway 
and its interaction with the classical apoptotic pathway in a SOD-1G93A transgenic 
ALS mouse model. Each of these pathways plays a unique role in disease 
progression. Deletion of Sarm1 did not extend lifespan, but it did affect disease 
onset and progression. SOD-1G93A Tg, Sarm1-/- mice tended to show trembling of 
the hindlimbs during a tail suspension test (an early sign of the disease; 
neurological score 1) before SOD-1G93A Tg animals. Combined with delayed late 
stage development, this led to a prolonged duration of the early stage of the 
disease in SOD-1G93A Tg, Sarm1-/- mice.  
NMJ alterations present prior to symptom onset in the SOD-1G93A Tg
mouse line (Mancuso et al 2011; Casas et al 2013). NMJ denervation in the 
tibialis anterior muscle is delayed in SOD-1G93A Tg, Sarm1-/- animals compared to 
SOD-1G93A Tg animals. By P120, however, near the onset of symptoms, partial 
and total denervation is similar. Therefore, it is not surprising that delayed NMJ 
denervation in the tibialis does not track with symptom onset. There are two 
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waves of denervation that occur: first, the fast fibers are denervated, followed by 
a second wave of the more resistant fast fibers and some slow fibers (Hegedus 
et al, 2007). Delayed denervation of the tibialis, but not the gastrocnemius, 
suggests that deletion of Sarm1 may be protective for vulnerable fast fibers, 
specifically intermediate type IID fast fibers, since there is a significantly 
increased amount of these fibers in the tibialis compared to the gastrocnemius 
(Allen et al, 2001). 
The extended duration of the early phase is most likely due to delayed 
axon degeneration in Sarm1 knockouts at late time points. It should be noted that 
the number of animals in this cohort for each time point was small (n=3) and that 
delayed axonal degeneration was seen in two out of the three animals. Axon 
degeneration in one of the three P150 SOD-1G93A Tg, Sarm1-/- animals was 
similar to the SOD-1G93A Tg animals, while the other two were intact. These 
results point to P150 as a sensitive time point for axon degeneration in the SOD-
1G93A Tg ;Sarm1-/- and speaks to the rapid progression of axon degeneration in 
these animals. 
Sarm1-/- mice also showed a delayed ventral horn neuron cell body loss 
compared to the SOD-1G93A Tg mice at P150. The dying back hypothesis 
suggests that motor neuron cell death follows axon degeneration. Although 
Sarm1 does delay ventral horn neuron cell body loss, it is possible that this 
protection reflects delayed axon degeneration. This hypothesis seems likely 
because (1) Sarm1 knockout delays axon degeneration in a number of different 
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contexts and (2) ventral horn neuron cell body loss proceeds very quickly (P150 - 
P165) in SOD-1G93A Tg, Sarm1-/- animals. Delayed NMJ denervation, axon 
degeneration, and neuronal cell body loss, without an extension in lifespan 
follows closely with the more rapidly progressing late phase seen in the SOD-
1G93A Tg, Sarm1-/- animals. 
The role of Bax in the SOD-1G93A Tg ALS mouse model 
We replicated results seen previously when blocking the apoptotic 
pathway through a Bax deletion in the SOD-1G93A Tg mouse (Gould et al, 2006). 
Lifespan of SOD-1G93A Tg animals was extended by ~20 days, NMJ denervation 
was delayed, and an increased number of motor neuron cell bodies persisted 
until endstage. That study was the first to identify the specific loss of large 
diameter motor neuron axons and cell bodies and specific preservation of small 
diameter motor neuron axons and cell bodies at endstage. The total number of 
neuronal cell bodies did not decrease at endstage, whereas large ventral horn 
NeuN+ cell bodies did. Thus, the ventral horn neurons remaining at endstage 
included both pre-existing small diameter neurons and large diameter neurons 
that atrophied and shrank in diameter. This suggests that although ventral horn 
neuron cell bodies are protected by deletion of the apoptotic pathway, the 
neurons that remain at endstage of the disease are most likely non-functional. 
This interpretation is consistent with the fact that even though cell bodies remain 
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in the SOD-1G93A Tg, Bax-/- animals, the animals still proceed through all stages of 
disease progression, including complete paralysis. 
The lifespan of SOD-1G93A Tg, Bax-/- animals correlates best with the 
delayed disease onset, which likely reflects delayed NMJ denervation. Duration 
of the disease is similar in SOD-1G93A Tg, Bax-/- and SOD-1G93A Tg animals (Fig 
2.4A). We found that the late stage of the disease is significantly extended in the 
SOD-1G93A Tg, Bax-/- compared to the SOD-1G93A Tg. One possibility is that this 
extended late phase is due to an increased amount of collateral axonal sprouting. 
Small fibers retain the ability to regenerate (Frey et al, 2000; Pun et al, 2006) and 
SOD-1G93A Tg, Bax-/- mice have an increased number of small diameter axons, 
which may be able to sprout and reinnervate the muscle. Therefore, we cannot 
rule out the possibility that the NMJ phenotype observed in P90 SOD-1G93A Tg 
;Bax-/-  mice reflects reinnervation by an increased number of collateral axons 
rather than delayed denervation. The reinnervation hypothesis may be a better 
explanation for the prolonged late phase, but because these effects happen long 
before disease onset, it is difficult to infer from these results which hypothesis is 
correct. 
The synergistic role of Bax and Sarm 
Most interestingly, we were able to explore the synergistic role of both 
these pathways in the SOD-1G93A Tg animal through a double genetic deletion of 
Bax and Sarm1. Surprisingly, the SOD-1G93A Tg, Bax-/-Sarm1-/- was able to further 
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delay disease onset significantly from both the SOD-1G93A Tg and more 
interestingly, from the SOD-1G93A Tg, Bax-/- mice. The SOD-1G93A Tg, Bax-/-Sarm1-
/- mice had an extended lifespan similarly to the SOD-1G93A Tg, Bax-/- mice (Fig 
2.2A), but a duration of symptomatic stages that was half that of the SOD-1G93A
Tg and SOD-1G93A Tg, Bax-/- animals (Fig 2.4A). The delayed symptom onset 
correlated with the delay in neuromuscular junction denervation similar to the 
SOD-1G93A Tg, Bax-/- mice in the gastrocnemius and further in the tibialis anterior. 
It is unclear at this time what the reason is for the further delay in denervation 
attributed by Sarm1 deletion alone in the tibialis, but it is consistent with the even 
greater effect seen in the Bax-/-Sarm1-/- mice in the tibialis.  
Double knockout of Bax  and Sarm1 delays large motor neuron axon 
degeneration better than Bax or Sarm1 knockout alone. This likely reflects a Bax-/- 
mediated delay in neuromuscular denervation and Sarm1-/- mediated axonal 
protection. Small diameter ventral horn neuron cell bodies were equally well 
protected in SOD-1G93A Tg, Bax-/-Sarm1-/- and SOD-1G93A Tg, Bax-/- mice at 
endstage of the disease. It is worth noting that while not significant, P150 SOD-
1G93A Tg, Bax-/- mice had a trend towards a decreased number of large cell bodies 
in the ventral horn. It seems, therefore, that the SOD-1G93A Tg, Bax-/-Sarm1-/- mice 
had better protection of large cell bodies at this timepoint. If SOD-1G93A Tg, Bax-/-
and SOD-1G93A Tg, Bax-/-Sarm1-/- mice had been analyzed at another time point 
closer to endstage, we may have been able to discern a difference in a ventral 
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horn neuron cell body protection. All of these results are consistent with the more 
rapidly progressing symptomatic stage seen in the SOD-1G93A Tg, Bax-/-Sarm1-/-. 
These results support other groups’ findings of the importance of 
denervation at the NMJ in the onset of ALS disease. Axon degeneration plays an 
important role in disease progression and in determining lifespan. Ventral horn 
neuron cell bodies can be preserved, even at endstage of the disease, whereas 
axon degeneration always occurs. This points to the importance of determining 
the underlying causes of neuromuscular denervation and axon degeneration. 
Sarm1 was able to delay degeneration of the axon slightly, but its inability to 
completely protect axons implies that other molecular pathways are involved in 
axon degeneration in the SOD-1G93A Tg mouse model of ALS.  
Future Directions 
While this study elucidates the roles of Bax and Sarm1 genes in 
phenotypic disease onset and progression as well as anatomical features of the 
“dying back” of motor neurons in the SOD-1G93A mouse model, there are still 
some outstanding questions in the field. These studies addressed the role of the 
apoptotic and Wallerian degeneration pathways in this disease, but the cellular 
site at which the genes act remains unknown. While it is thought that deleting 
Bax and Sarm1 prevents neuronal cell death in a neuron specific manner, there 
is also a known non-cell autonomous role of mutant SOD-1 in these mouse 
models. The experiment to answer whether this effect occurs cell autonomously 
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would be to knock out both of these genes conditionally in motor neurons using 
either a Chat-Cre or Hb9-Cre mouse line. These experiments have obvious 
limitations that crossing another allele would make getting the number of mice 
needed for statistical analysis challenging, however, this approach would answer 
whether deletion of these two pathways exhibit its effects in a cell autonomous 
manner. 
Also, in addition to the histological characterization that was already done, 
further experiments would be able to answer what is occurring on a finer scale in 
the ventral root and neuromuscular junction synapses. With the current results, 
we are unable to determine the effect of deleting the apoptotic and Wallerian 
degeneration pathways on reinnervation at the NMJ. Electron micrograph 
analysis at the neuromuscular junction would answer which of the synapses are 
reinnervated. Since this balance of denervation/reinnervation of synapses at the 
NMJ regulates symptom onset, it is possible by enhancing reinnervation, one 
could delay symptom onset further. Targeting this mechanism might be another 
potential way to mitigate disease symptoms. 
Another experiment to do would be to look at the later time points (around 
P170-180) in the Bax-/- and Bax-/-/Sarm1-/- animals. It is likely, since the 
histological analysis of Bax-/-/Sarm1-/- animals showed an even greater effect 
compared to Bax-/- alone, that this later time point may show an even further 
protection, specifically of large neurons and MMP-9 expressing cells in the 
ventral spinal cord, and possibly even axons in the ventral root. Based on 
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symptomatic stage data from the neurological scoring, it is likely that this late 
time point would be a sensitive one for the Bax-/-/Sarm1-/- animals with either all 
animals showing protection or a subset of them showing protection. Addressing 
these questions would provide a clearer role for each of these pathways in the 
mechanism of the ‘dying back’ nature of motor axons in the SOD-1G93A mouse 
model of ALS. 
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Chapter 6: Materials and Methods 
Animal models 
All experiments using animals were performed in accordance with NIH guidelines 
and approved by the Institutional Animal Care and Use Committee at the 
Rockefeller University. Mice null for Bax (Knudson et al, 1995) and SOD-1G93A Tg 
mice (B6.Cg-Tg(SOD1-G93A)1Gur/J)  were obtained from The Jackson 
Laboratory. SOD-1G93A mice expressed a high copy number of the human SOD-1 
gene, which harbors a glycine to alanine mutation at the 93rd codon of the SOD-1 
gene. Bax-/- and Sarm-/- mice were mated to generate Bax+/-/Sarm+/- females. The 
Bax/Sarm heterozygotes were then cross with Tg[SOD-1-G93A] male mice to 
yield the following genotypes for analysis: SOD-1WTBax+/+,Sarm+/+; SOD-1WT Bax-
/-,Sarm+/+; SOD-1WTBax+/+,Sarm-/-; SOD-1WTBax-/-,Sarm-/-; SOD-1G93A 
Tg,Bax+/+,Sarm+/+; SOD-1G93A Tg,Bax-/-,Sarm+/+; SOD-1G93A Tg,Bax+/+,Sarm-/- and 
SOD-1G93A Tg,Bax-/-,Sarm-/-. All comparisons in this study were between 
littermates and housed together to minimize environmental factors. Mice were 
genotyped using PCR protocols from the Jackson Laboratory. The mice were 
housed with free access to water and SulfaTrim rodent chow. The mice were 
divided into two cohorts.  One was dedicated to determining survival, symptom 
onset and progression through neurological scoring, body weight loss, and 
endstage histology. The other was used for histological analysis at various time 
points during disease progression: P50, P90, P120, and P150. 
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Table 6.1 Genotypes analyzed in this study: 
Genotype: 
SOD-1WTBax+/+Sarm+/+ SOD-1G93A Tg; Bax+/+Sarm+/+ 
SOD-1WTBax-/-Sarm+/+ SOD-1G93A Tg; Bax-/-Sarm+/+ 
SOD-1WTBax+/+Sarm-/- SOD-1G93A Tg; Bax+/+Sarm-/- 
SOD-1WTBax-/-Sarm-/- SOD-1G93A Tg; Bax-/-Sarm-/- 
Survival, symptom onset, ALS disease progression 
Survival, symptom onset, disease progression, and body weight loss were 
assessed in one cohort (n= 8-9 for each genotype; 8 different genotypes listed 
above). Symptom onset and disease progression were assayed using the 
neurological scoring system guidelines from The Jackson Laboratory 
(http://jackson.jax.org/rs/444-BUH-304/images/Working_with_ALS_Mice.pdf). 
Mice were assessed by two experimenters every other day starting at P50 for the 
duration of their lifespan. Mice were scored as follows: Score 1: trembling of the 
hind legs during a tail suspension test; Score 2: toes curl under foot during 
walking; Score 3: hind limb paralysis; Score 4: terminally paralyzed (unable to 
right themselves after 30 seconds of being placed on each side). Animals were 
euthanized upon reaching score 4. Body weight measurements were collected 
daily beginning at P50 and through score 4 for mice carrying the SOD-1G93A allele 
or until P200 for SOD-1WT controls. 
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Rotorod behavioral assay 
Motor performance of mice was tested using the rotorod behavioral assay. A 
modified protocol was created and tested to accommodate a large cohort. Each 
mouse was tested when they reached P50, P90, P120, P150 and P180. This 
cohort was also used for histological analysis, so three mice were removed at 
each timepoint resulting in P50 (n = 15 per genotype), P90 (n = 12 per genotype), 
P120 (n = 9 per genotype), P150 (n = 6 per genotype), and P180 (n = 3 per 
genotype). The modified protocol to test the behavioral function was to (1) place 
the mice on the rotorod at a non-accelerating speed until each mouse stayed on 
successfully for 1 minute, (2) run three trials with an acceleration of 5 RPM, (3) 
give the mice a 1 minute break, and (4) run three trials with an acceleration of 5 
RPM and record these three times. The average of the three trials was plotted for 
each mouse. 
Tissue collection 
Mice were anesthetized and perfused with PBS followed by 4% 
paraformaldehyde-PBS. For cohort 1, SOD-1G93A Tg mice were euthanized when 
they reached score 4 and SOD-1WT animals were euthanized at P200 to 
represent endstage. A second cohort was used to collect histological samples at 
P50, P90, P120 and P150 (n=3 per time point per genotype). Whole mice were 
placed on ice for 20 minutes after perfusion for further fixation. The sacral spinal 
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cord, sacral ventral root, tibialis anterior and gastrocnemius muscles were 
dissected and postfixed. 
Neuromuscular Junction Analysis 
Following dissection, the gastrocnemius and tibialis anterior muscles were 
postfixed in 4% paraformaldehyde-PBS overnight, then washed 3x with 1x PBS 
and transferred to a 2:1 OCT:30% sucrose-PBS solution for 3 days. Samples 
were frozen in OCT using an isopropanol/dry ice bath and the cryopreserved 
samples were sectioned longitudinally (80 μm). The tissue was permeabilized in 
1% Triton X-100/PBS for 1 hour and then blocked overnight in 0.1% Triton X-
100/PBS containing 10% donkey serum at 4°C. Muscles were stained with rabbit 
anti-synapsin (1:200, Synaptic Systems) in blocking buffer at 4°C for at least 24 
hours. After four 1-hour washes using 0.1% Triton X-100/PBS, muscles were 
incubated with donkey anti-rabbit Alexa 594 antibody (1:1000, Invitrogen) and α-
bungarotoxin, fluorescin conjugated (1:1000, Invitrogen) for 24 hours. Sections 
were then washed in PBS four times and coverslips were mounted using 
Fluromount-G (SoutherBiotech). Imaging of samples was performed with a LSM 
510 laser scanning confocal microsome (Leica). To analyze presynaptic 
terminals, maximum-intensity projections of z-stack images for each muscle 
sample were generated using FIJI software. Postsynaptic AChR (α-bungarotoxin-
positive) sites not apposed by synapsin were counted as denervated. Synapses 
with less that 50% overlap were described as partially denervated. Approximately 
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100 neuromuscular junctions were examined for both gastrocnemius and tibialis 
anterior muscles for all time points and genotypes. 
Axon counts and electron microscopy 
Ventral roots were stored in 4% paraformaldehyde/2.5% glutaraldehyde in 0.1 M 
sodium cacodylate buffer overnight at 4°C. Subsequently, the samples were 
post-fixed in 1% osmium tetroxide for one hour on ice, stained with 1% Uranyl 
acetate for 30 minutes at room temperature, dehydrated with increasing 
concentrations of ethanol, and infiltrated/embedded in Eponate12 resin. Ultrathin 
70 nm sections were cut and examined no the electron microscope (100CX 
JEOL, Tokyo, Japan) at 80 kV with a digital imagin system (XR41-C, Advantage 
Microscopy Technology Corp, Denver, MA). For quantification, large and small 
diameter axons were counted as either intact or degenerated if any sign of 
fragmentation was observed. 
Neuron number in the ventral horn of the spinal cord 
The sacral level of the spinal cord was fixed overnight in 4% paraformaldehyde-
1XPBS solution. Samples were then washed 3x with PBS and transferred to a 
2:1 OCT:30% sucrose/PBS solution. Spinal cords were frozen in OCT in an 
isopropanol/dry ice bath and then sectioned into 12 μm thick sections. Spinal 
cord sections were stained with antibodies: mouse anti-NeuN (1:1000, 
Chemicon) and goat anti-MMP-9 (1:200, Sigma-Alrich). The average number of 
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NeuN+, large NeuN+ (>10μm) and MMP-9+ expressing neurons in the ventral 
horn of eight spinal cord sections per animal is reported. 
Statistical analysis 
Statistical significance of survival and body weight loss was determined using a 
Log-rank test and is represented as median days of survival +/- SEM. A one-way 
ANOVA statistical test was used to test differences between genotypes in the 
duration of different stages of the disease, neuromuscular junction innervation 
(comparing different genotypes at various timepoints), and large and small axon 
number (comparing genotypes at various timepoints). A one-way ANOVA 
statistical test was used to determine differences in neuron number (NeuN+, 
large NeuN+, and MMP-9+) within one genotype at the different timepoints. 
Table 6.2 Antibodies used in this study 
Antibody Source 
Rabbit anti-synapsin Synaptic systems 
Alexa 488-conjugated a-bungarotoxin Invitrogen 
Mouse anti-NeuN Chemicon 
Goat anti-MMP-9 Sigma Aldrich 
Rabbit anti-peripherin Millipore 
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Mouse anti-tuj Invitrogen 
Mouse anti-GFAP Millipore 
Rabbit anti-GFP Abcam 
Rabbit anti-HB9 Sam Phaff 
Primary astrocyte culture 
Glial monolayers were prepared from SOD-1G93A Tg or their nontransgenic 
littermate (WT) cortex P0 pups. Cortices were triturated 20-25x with a pipetman 
to cells were plated in glial medium: DMEM (Invitrogen) containing 10% FBS 
(Invitrogen) and 100 U of penicillin and streptomycin antibiotics (Invitrogen). Cells 
were allowed to grow for ~2 weeks to reach confluency. 
Astrocyte conditioned medium 
After glial cells became confluent, cells were shaken for 1 hour at room 
temperature at 100 rpm to remove microglia. The supernatant was then removed 
and replaced with motor neuron cell medium. At 7 days, we collected the 
conditioned medium, centrifuged it for 1000g for 5 minutes to eliminate floating 
cells. The conditioned medium was filtered and frozen down at -80°C. Before use 
on motor neurons, penicillin/streptomycin/glutamine plus cocktail of trophic 
factors was supplemented into the conditioned medium. 
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Primary motor neuron culture 
Spinal cords from E12.5 WT CD-1 mice or HB9-GFP1 Tmj transgenic mice were 
dissected from embryos in Hibernate-E medium. Spinal cords were trypsinized 
with 0.05% trypsin (Invitrogen) for five minutes, run through 4% filtered BSA 
cusion at 500 rpm for 5 minutes, centrifuged through a 5.2% sucrose gradient 
made with optiprep solution in 4.4% Tricine buffer for 15 minutes at 800 rpm. The 
cells were then washed once with neurobasal medium (Invitrogen) and spun 
down at 1000 rpm for 5 minutes. The supernatant was removed and cells were 
resuspended in motor neuron medium containing B27, 
penicillin/streptomycin/glutamine, and a cocktail of neurotrophic factors including 
10 ng/mL of brain-derived neurotrophic factor, 10 ng/mL of glia-derived 
neurotrophic factor, 10 ng/mL of NT-3, and 25 ng/mL of ciliary neurotrophic 
factor. Motor neurons were plated on plastic 8-well slides at 1500 cells/cm2 
coated with poly-D-lysine/laminin. 
Ventral explant cultures 
Spinal cords from E12.5 WT CD-1 mice were dissected carefully out of the 
embryo in Hibernate-E medium. The spinal cords were cut along the dorsal horn 
so as to flatten out the spinal cord. The dorsal section of the spinal cord was then 
cut from the ventral section of the spinal cord. The ventral spinal cord was then 
cut into 8 even sections horizontally and each section was cut another 8 times 
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horizontally and vertically. These ventral explants were then plated on plastic 8-
well slides coated in poly-D-lysine/laminin. 
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Appendix 1: SOD-1WT Histology 
In parallel with all of the SOD-1 Tg histological samples that were 
collected, control SOD-1WT samples were also collected at the neuromuscular 
junction, ventral root, and spinal cord at all of the different timepoints analyzed 
above (P50, P90, P120, P150, and ES). Representative images of endstage 
SOD-1WT and SOD-1G93A Tg animals and quantification of innervated synapses is 
shown in A1.1. Motor axons in the ventral root at each timepoint are shown in 
A1.2 and neuron cell body number is shown in A1.3 and A1.4. 
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Figure A1.1. Neuromuscular junction innervation at endstage. 
Representative images of neuromuscular junction of ventral root samples 
dissected from SOD-1WT, SOD-1WT,Bax-/-Sarm+/+, SOD-1WT,Bax+/+Sarm-/-, and 
SOD-1WT,Bax-/-Sarm-/-, SOD-1G93A Tg, SOD-1G93A Tg, Bax-/-Sarm+/+, SOD-1G93A
Tg, Bax+/+Sarm-/-, and SOD-1G93A Tg, Bax-/-Sarm-/- animals (n=3 for each 
timepoint) at endstage (P200 for SOD-1WT animals and when the animals 
reached score 4, or paralysis for SOD-1 Tg animals). α-bungarotoxin was used to 
label postsynaptic sites (green) and synapsin antibody (red) labeled presynaptic 
sites of the neuromuscular junction in the gastrocnemius muscle. Yellow was 
counted as completely innervated synapses, yellow and green (indicated by 
white arrows) were counted as partially innervated synapses, and green only 
were counted as denervated synapses. 
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Figure A1.2. Motor axon degeneration in ventral root. Representative 
electron micrograph images taken of ventral root samples dissected from (A) 
SOD-1WT, (B) SOD-1WT,Bax-/-Sarm+/+, (C) SOD-1WT,Bax+/+Sarm-/-, and (D) SOD-
1WT,Bax-/-Sarm-/- animals (n=3 for each timepoint) when each reached P50, P90, 
P120, P150, and P200 (ES). 
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Figure A1.3. Neuron cell body in ventral horn of spinal cord. Representative 
images of NeuN+ stained 12 μm spinal cord sections labeling cell bodies in (A) 
SOD-1WT, (B) SOD-1WT,Bax-/-Sarm+/+, (C) SOD-1WT,Bax+/+Sarm-/-, and (D) SOD- 
1WTg,Bax-/-Sarm-/- animals (n=3 for each timepoint) were dissected when each 
reached P50, P90, P120, P150, and P200, or endstage. Quantification of (E) total 
NeuN+ neurons and (F) large NeuN+ neurons (>10 μm) located in the ventral 





Figure A1.4. MMP-9+ cell body in ventral horn of spinal cord. Representative
images of MMP-9+ stained 12 μm spinal cord sections labeling cell bodies in (A) 
SOD-1WT, (B) SOD-1WT,Bax-/-Sarm+/+, (C) SOD-1WT,Bax+/+Sarm-/-, and (D) SOD-
1WTg,Bax-/-Sarm-/- animals (n=3 for each timepoint) were dissected when each 
reached P50, P90, P120, P150, and P200, or endstage. (E) Quantification of 








Appendix 2. MMP-9+ cells at all timepoints in SOD-
1G93A Tg animals 
MMP-9 labeled cells were shown for P150 and endstage timepoints in the 
results section of this thesis to indicate the latest timepoint that showed 
protection in Bax KO, Sarm KO, and Bax/Sarm dKO lines. Shown below are all of 
the other earlier timepoints that showed protection (P50, P90, and P120). All 
results in A2.1 showed similar protection at these timepoints comparatively to the 
P150 timepoint in the genetic knockouts. 
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Figure A2.1. MMP-9+ cell body in ventral horn of spinal cord. Representative
images of MMP-9+ stained 12 μm spinal cord sections labeling cell bodies in (A) 
SOD-1G93A Tg, (B) SOD-1G93A Tg, Bax-/-Sarm+/+, (C) SOD-1G93A Tg, Bax+/+Sarm-/-, 
and (D) SOD-1G93ATg, Bax-/-Sarm-/- animals (n=3 for each timepoint) were 
dissected when each reached P50, P90, P120, P150, and endstage.  
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Appendix 3. Treatment of infection with antibiotics 
In the middle of the study we were conducting, we noticed something odd 
occurring. The mice that contained the SOD-1G93A transgene were dying earlier 
than their expected lifespan of ~P165 and they were progressing very rapidly 
from Score 2 to Score 4, irrespective of genotype (Figure A3.1). This 
phenomenon was ensuing with all animals that reached late stage, while WT 
animals were unaffected. Blood samples were collected and pathological 
analysis was done on these mice that died early. No extreme abnormalities were 
discovered from this analysis. 
We decided that it was possible that the mice may be harboring some sort 
of infection, so we treated the mice with broad-spectrum antibiotics. The problem 
resolved itself in mice treated with two weeks of SulfaTrim rodent chow. All mice 
without two weeks of treatment were removed from the analysis and some mice 
from Cohort 2 were added to this cohort to compensate for the loss of mice. 
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Figure A3.1 Abnormalities in disease progression of SOD-1G93A Tg animals. 
A) Time when mice reached neurological score 2 and B) reached score 4, the
phenotype at which they were sacrificed. SOD-1G93A Tg animals (black line) 
(n=3), SOD-1G93A Tg/Sarm KO (green line) (n=2), and SOD-1 Tg/Bax KO/Sarm 
KO (red line) (n=1). Survival of mice correlated with onset of Score 2. 
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